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Microbiology

An interdisciplinary approach to target elucidation of novel triazole antibiotic 31G12
Chairperson: Dr. Nigel Priestley, Department of Chemistry
Staphylococcus aureus is a Gram-positive bacterial pathogen responsible for nosocomial and
community-acquired infections that can quickly acquire antibiotic resistance. We have identified
a novel triazole antimicrobial 31G12 based on the natural product core of nonactin isolated from
the fermentation of Streptomyces griseus, that is active against many Gram-positive bacteria as
well as antibiotic resistant methicillin-resistant S. aureus and vancomycin-resistant
Enterococcus. The synthesis and characterization indicate that 31G12 exists as a mixture of two
rotamers at room temperature and displays bacteriostatic activity against S. aureus with moderate
mammalian cell toxicity. We have currently identified potential protein targets of 31G12 in S.
aureus via an interdisciplinary approach to the target elucidation. First, a chemical proteomic
strategy using photoaffinity labeling revealed a potential target protein at approximately 110 kDa
when visualized via western blot and in-gel scans. Second, whole-genome sequencing and a
bioinformatics approach revealed two potential proteins, thioredoxin-fold protein and L11
methyltransferase to be good candidates based on dose-response curves. Although the mode of
action has not been established, this work provides a rational framework to expand the efficacy
of this novel class of antimicrobials through structure-based drug design to improve potency
against Gram-positive bacteria and reduce mammalian cell toxicity.
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CHAPTER 1. Introduction
Public Health Concerns
Antimicrobial resistance has become a global health concern.1 Antimicrobial resistance
is defined as resistance of a microorganism to an antimicrobial against which it was originally
sensitive. Today, most of the infectious agents of concern to the public health have become
antimicrobial resistant. The United States Center for Disease Control and Prevention (CDC)
estimates that infections caused by AMR bacteria resulted in two million cases of illness and
23,000 deaths in the U.S. annually. The current AMR pandemic has been suggested to be caused
by overprescribing and overuse of antimicrobials in hospitals, agriculture, and livestock settings
and also the lack of viable drug alternatives.1,2 The lack of discovery of new classes of antibiotic
threatens to continue the AMR pandemic. Pharmaceutical companies are often reluctant to
invest in antimicrobial research and development due to the unfavorable returns- on- investment
therefore placing the burden of new development on private companies.3 The BARDA
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator has partnered with
public-private companies to provide funding to address the growing need for new antimicrobials.
The World Health Organization (WHO) has listed six high-priority bacteria that includes
methicillin-resistant Staphylococcus aureus (MRSA). S. aureus colonizes between 30% and
50% of the skin or nasopharynx.4 The SENTRY Antimicrobial Surveillance Program
demonstrated that S. aureus was the most prevalent cause of nosocomial and communityacquired bloodstream infections, skin and soft tissue infections, and pneumonia. This can be
partly attributed to the survivability of S. aureus in acidic, high salt concentration, and widetemperature variation environments.5 Before the introduction of antimicrobials, the mortality
rate of invasive infections was approximately 90%.6 Resistance to penicillin was noted soon
1

after its first clinical trials in the 1940s.7 This rapid acquisition of resistance soon led to the
isolation of MRSA almost immediately after the introduction of methicillin. The CDC reported
that after the introduction of MRSA into a hospital, 87.5% of hospital’s retain persistent MRSA
isolates.8 Resistance to the last resort antimicrobial, vancomycin, was first documented in 1997
making certain strains of S. aureus resistance to all antimicrobials developed.9 There is a
pressing need for development of new antimicrobials to combat the treat of AMR and tackle this
serious public health challenge.
Bacterial Acquisition of Antibiotic Resistance
The emergence of antibiotic resistance closely mirrors that of the discovery of antibiotics
due to the bacterial genetic plasticity to develop resistance. The cause for this new era of
resistance can be seen in the overuse, inappropriate prescribing, extensive agricultural use,
availability of few new antibiotics and regulatory barriers.10 In order for bacterial to persist in
threatening environments when exposed to antibiotics they use two major strategies of gaining
resistance to adapt to the environment, including genetic or mechanistic bases of antimicrobial
resistance.
In the presence of an antimicrobial a bacterium can acquire foreign DNA coding for
resistance through horizontal gene transfer (HGT) or develop mutations in genes often associated
with the mechanisms of action at a cost to cell fitness.11 HGT proceeds through three strategies,
including transformation (incorporation of naked DNA), transduction (phage mediated) and
conjugation (bacterial “sex”). To counter antibiotics with different mechanisms of action,
bacteria have evolved multiple mechanisms of drug resistance for continued survival. Antibiotic
resistance mechanisms can be classified by the route involved in resistance, including;
modification of the antimicrobial compound, prevention of the drug reaching the antibiotic
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target, changes and/or bypass of target site and global cell adaptive processes.11 Modification of
the antibiotic molecule is achieved by adding specific chemical moieties such as acetylation,
phosphorylation, and adenylation which create steric hindrance at the active site on the target or
enzymatic destruction of the antibiotic molecule itself. Many antibiotic targets reside within the
cell and molecules must therefore penetrate the cell to exhibit their effects. Bacteria have
combated these mechanisms of action by decreasing the uptake of the molecule or by the
production of efflux pumps to extrude the compound from the cell. A common strategy of
bacteria is to modify the target site to decrease affinity for the antibiotic molecule or prevent the
antibiotic from binding altogether to protect the target site. Modification of the target site can
include point mutations in the respective gene, enzymatic alterations of the binding site through
addition of different moieties or bypassing the original target. The last adaptation utilized by
bacteria is global cell adaptation in which bacteria evolve to cope with the stressful situations
without disrupting vital cellular processes.
Origin and History of Antibiotics
Antimicrobials have saved countless number of lives and helped to control infectious
diseases. Antimicrobials have been used for millenia to treat infections, nevertheless the
beginning of the “modern antibiotic” era was established with the discovery of penicillin in 1928
by Alexander Fleming.10,12
Between 1930 and 1962 more than twenty novel classes of antibiotics were discovered.
The most common classification scheme is based on their molecular structure, mode of action, or
spectrum of activity.13 Some common classes of antibiotics include beta-lactams, macrolides,
tetracyclines, quinolones, aminoglycosides, sulfonamides, glycopeptides and Oxazolidinones.
Beta-lactams were the first class of antibiotics to be discovered. They are classified
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based on their cyclic amid composed of 3-carbons and 1-nitrogen that interferes with bacterial
cell wall synthesis to either kill or inhibit growth. Beta-lactam antibiotics bind to penicillinbinding proteins (PBP), which are responsible for cross linking peptide units during
peptidoglycan synthesis.14 The most common antibiotics of this class include penicillins,
cephalosporins, monobactams and carbapenems.
Macrolides are metabolic products first isolated from the soil dwelling bacteria
Saccaropolyspora erythraea, and are characterized by 14-, 15-, or 16-membered macrocyclic
lactone rings with pendant carbohydrates. These antibiotics inhibit protein synthesis by binding
to the ribosome, thereby preventing the addition of subsequent amino acids to the growing
polypeptide chains.15 Antibiotic examples include erythromycin, azithromycin, and
clarithromycin.
Tetracyclines, like macrolides, were first isolated from soil bacterium genus Streptomyces
by Benjamin Duggar.16 These antibiotics target the ribosome to disrupt protein synthesis similar
to macrolides. This class of antibiotics displays a broad-spectrum of activity against both Grampositive and Gram-negative bacteria17. These antibiotics can be separated into different
generations, depending on whether they were obtained by biosynthetic methods, semi-synthetic
derivatives or total synthesis. First generation tetracyclines include tetracycline, oxytetracycline;
second includes generation doxycycline methacycline; and third generation is exemplified by
tigecycline.18
Quinolones were accidently discovered during development of antimalarial
chemotherapies based on the quinine structure. The bicyclic core structure has multiple
functional groups, but the greatest improvement in biological activity made by the addition of
fluorine at C6 to generate the fluoroquinolones and a more broad spectrum antibiotic.19
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Although the mechanisms of action are not well understood, it is accepted that quinolones inhibit
DNA synthesis by binding to the complexes formed between DNA and gyrase or
topoisomerase.20
Aminoglycosides, like other antibiotics, were first isolated from soil Actinmomycetes and
have been used extensively against Mycobacterium tuberculosis. These compounds are
composed of 3-aminosugars connected by glycosidic bonds and inhibit protein synthesis by
binding to the ribosomal subunits.21 While these antibiotics have been shown to be highly toxic,
they are still commonly used due to their broad-spectrum activity. Commonly used antibiotics
include gentamicin, neomycin and tobramycin.
The first effective clinically used antibacterial drugs were the sulfonamides, discovered in
1935 by Gerhard Domagk. Sulfonamides are structurally related to p-aminobenzoic acid which
is used in the synthesis of folic acid, leading to the mechanism of action that inhibits
tetrahydrofolic acid synthesis22.
Glycopeptides were initially isolated from soil Actinomycetes but current antibiotics are
semi-synthetic and contain the core of a cyclic peptide of seven amino acids, in which two are
bound to sugars23. These bulky structures inhibit bacterial cell wall peptidoglycan synthesis by
binding to the outside of the cell wall.24 These antibiotics tend to have high toxicity and include
vancomycin and teicoplanin.
The newest class of synthetic antibiotics are the oxazolidinones which include linezolid.
The mechanism of action is not fully understood for this class but evidence suggests that
inhibition of protein synthesis by binding to the ribosome occurs in this broad-spectrum
antibacterial.25,26
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Modern drug discovery methods
As previously discussed, the source of many antibiotics has been from soil-dwelling
microbes whose metabolites possess antimicrobial activity. From the natural products, the
compounds are synthetically modified to create new generations but the majority retain the same
mechanism of action. Today the increasing threat of increasing highly resistant bacteria calls for
an urgent need for new antibiotics. Three different approaches have been applied for new drug
discovery: bioactivity-guided screening of crude extracts produced from microorganisms,
chemical screening based on biological screening of chemical libraries, and target-oriented
screening that exploits known molecular targets.27,28
Natural products have been a major driving force for drug discovery since the antibiotic
Golden era from 1920-1940’s. These small-molecule metabolites are used as the basis for
combinatorial chemistry libraries which demonstrate increased hit rates in biological screening
campaigns.29 Benefits of these natural products include the complex molecular structures,
stereogenic centers and ability to interact with multiple proteins which is difficult to achieve with
solely synthetic antimicrobials.30 In order to enhance the bioactivity of natural products, the
biologically-relevant core is used as a scaffold for the synthetic addition of different functional
groups to produce compound libraries. These compounds are then biologically screened and
scored from increasing to decreasing activity and further chemical modifications are made to the
compounds in iterative rounds of development. The success of these chemical libraries depends
on the screening of hundreds of thousands of compounds that may require combinatorial multistep synthetic chemistry to produce.
Another approach to new drug discovery is in silico screening of target-oriented
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structures. This approach utilizes structure activity relationships (SAR) that aim to improve
potency, reduce toxicity and enhance bioavailability.31 Although these computational methods
cannot replace medicinal synthetic chemistry, computational methods can explore active sites to
elucidate and optimize biologically active structures. These methods can also be used in
screening campaigns against microbial specific targets thus reducing the toxicity to humans.
However, a major downfall is that these methods often require a 3D representation of the protein
to be used in computation analysis.
Target Elucidation Strategies
Historically there have been two main approaches to target elucidation in drug discovery;
those being phenotype-based drug discovery (PDD) and target-based drug discovery (TDD). In
the phenotype-based approach, an assay is first developed to screen a library of compounds for
an observable phenotypic change, such as fluorescence based resazurin reduction assay to
monitor cell viability.32,33 From these libraries, the top candidates are then used for target
deconvolution and ultimately target identification. An advantage of phenotypic screening is that
is does not rely on knowing the target and it capable of testing complex biological mechanisms
that may include multiple targets.34 A downfall of PDD is that the flow scheme from hit to target
elucidation tends to be more complicated and nonlinear due to the unknown target(s) of the
tested compounds.35
Target-based drug design has been broadly used in the post-genomic era for target
elucidation. Unlike PDD, TDD is hypothesis driven based on specified molecular targets, which
have been elucidated from bioinformatics to have an important role in disease.36,35 Drugs can
then be designed using a SAR approach and later screened in target-specific assays to determine
drug hits and leads.33 A downfall of TDD approaches is the dependence on molecular biology
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for protein purification or creation of cell lines that overexpress the target and therefore the
assays are based on these recombinant proteins.35 A pitfall of drug discovery is the target
validation which links the specific molecular target to the in vivo model and indicates drug
efficacy.35,37 Whether the target elucidation strategy is phenotype or target-based, both methods
are vital to the production of new molecular targets that will aid in the improvement of drug
discovery.
Nonactin
Natural products serve as an important scaffold for the development of new
antimicrobials with a diverse array of properties. Nonactin is a macrotetrolide antibiotic,
produced by soil-dwelling Streptomyces griseus. The macrocyclic ring consist of two units of
(+)—nonactate and two units of (-)—nonactate in an altering arrangement of (+)-(-)-(+)-(-), such
that nonactin is achiral.38 Nonactin can be separated into its monomeric methyl nonactate by
methanolysis of nonactin followed by resolution using Rhodococcus under aerobic and anaerobic
conditions.39 This methyl nonactate core is the scaffold for a highly diverse combinatorial
library that displays a range of pharmacological activity against both Gram-negative and Grampositive bacteria.38 This library can further be broken down into the heterocyclic compounds of
1,2,3-triazoles prepared from the copper catalyzed cycloaddition of terminal alkynes and azides,
Figure 2.2 key intermediate 5 and 16, and amide bond formation prepared from an acyl chloride
and amine, Figure 2.2 key intermediate 5 and 8.
Further investigation using biological screening of triazole compounds suggested that the
complex stereochemistry of the nonactin core contributed to its selective antibiotic activity.40 It
was demonstrated that the (+)—nonactic acid, not the (-)—nonactic acid contributed to the
observed antimicrobial killing. Through the biological screening of a large library of nonactic
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acid analogs against Gram-positive and Gram-negative bacteria it was discovered that the library
consisted of compounds active against vancomycin-resistant E. faecalis (VRE) and methicillinresistant S. aureus (MRSA). The screening campaigns yielded the compound 31G12, which had
the greatest biological activity was selected for further studies involving target elucidation.
Purpose of Research
The emergence of resistant strains of bacteria, the limited number of new antibiotics
brought to market, and the declining interest from medical companies into new antibiotic
development has raised concern for the future of treatment of bacterial infections.41,42 With the
number of multidrug-resistant bacteria ever increasing, the pursuit of new antibiotics with novel
modes of action needed to combat infections. Our lab has previously used a natural product core
scaffold, nonactin, to synthesize a library of compounds with varying degrees of activity. From
this library of compounds, 31G12 showed the most potent killing of Gram-positive bacteria and
was selected for further studies to elucidate the mechanism of action. However, the mechanisms
of action for these new antibiotics still remains a mystery. Herein lies the genesis of my research
on finding the mechanism of action for novel triazole antibiotic 31G12. This project was
approached using multiple methods of target elucidation, including photoaffinity probe labeling
and bioinformatics. The hypothesis is that these novel antibiotics, which are selective against
VRE and MRSA, will yield a novel mechanism of action and novel class of antimicrobials to
contribute to the field of antimicrobial development.
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CHAPTER II: 31G12 Synthesis, Characterization and
Resistance to S. aureus
Introduction
Bacterial infections have become a serious public health threat.1 Antimicrobial resistance
(AMR) in bacterial pathogens has led to increased infections and mortality rates worldwide.43
The current AMR pandemic has been suggested to be caused by overprescribing and overuse of
antimicrobials in hospitals, agriculture, and livestock settings and the lack of viable drug
alternatives.1,2 The lack of new classes of antibiotic discovery threatens to continue the AMR
pandemic. Staphylococcus aureus is a Gram-positive bacteria and a major cause of nosocomial
and community acquired infections.44 This bacteria is the leading cause of bacteremia and
infectious endocarditis as well as skin, soft tissue, and device-related infections.45 The
emergence of methicillin-resistant S. aureus (MRSA) has complicated treatment options for such
infections.46 Enterococcus faecalis is a Gram-positive bacterium and is commonly an
opportunistic pathogen and cause of nosocomial infections.47 A last resort treatment for Grampositive bacteria is vancomycin. The emergence of vancomycin-resistant enterococcus (VRE)
and vancomycin-resistant S. aureus has further limited treatment options.47,48 It has become
clear that multidrug resistance is spreading at an alarming rate.43 Unfortunately, the need for
new antibacterial therapeutics has not been met, with only five new classes of antibiotics
marketed since 2000.49 During the golden-era of antimicrobial discovery, antibiotics were
initially isolated from natural products. Many natural products possess complex stereochemical
centers, and their structures can be used as scaffolds to develop novel, semi-synthetic
antimicrobial agents.50
The ability to identify new, potential targets in Gram-positive bacteria that can be used in
10

therapeutic intervention will contribute to the pressing need for new antibacterial therapeutics.51
In the search for new therapeutics, our interest in a natural product-derived combinatorial library
was based on the macrotetrolide antibiotic nonactin.52 Nonactic acid provides an unique scaffold
with the C-8 alcohol and C-1 ester functional groups (Figure 1.1) that allow for easy
diversification. The conversion of the C-8 alcohol into an azide allows the use of Cu-catalyzed
cycloaddition chemistry for easy elaboration, and the C-1 ester can readily be converted to
numerous amide derivatives (Figure 1.1).52 Through structure activity relationship studies of the
triazole combinatorial library, we have identified a lead antibacterial compound 31G12 ((S)-2((2S,5R)-5-((R)-2-(4-((4-(4-chlorophenyl)piperidin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)tetrahydrofuran-2-yl)-N-(3,4-dichlorophenethyl)-N-(thiazol-5-ylmethyl)propenamide),
that is biologically active against multiple species of bacteria including human pathogens such as
S. aureus, E. faecalis and drug-resistant MRSA and VRE (Table 1). Our hypothesis is that the
biological activity is due to a different mode of action relative to currently available antibiotics.
This study discusses the synthesis of the novel antibiotic 31G12 and its chemical and biological
characterization. S. aureus was used as a model pathogen to investigate the antimicrobial
properties of 31G12, including attempting to elucidate the target. The antibacterial
characteristics of 31G12 were further investigated in order to classify this novel antibiotic as
bacteriostatic against S. aureus with moderate toxicity to mammalian cells.
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Figure 2.1: The conversion of starting material methyl nonactate into the nonactic acid scaffold
with substituted triazole ring and an amide bond used in synthesis of a combinatorial library of
500 compounds. The structure activity relationship studies (SAR) yielded compound 31G12 as
the top lead for further studies in determining the mode of action.
Table 2.1: Minimum inhibitory concentrations (M) of lead compound 31G12 against Grampositive bacteria for.
Compound S. aureus
B. anthracis E. faecalis B. subtilis
MRSA
VRE
31G12
4
4
16
2
4
16

Materials and Methods
Synthesis of 31G12. Solvent and other reagents were ACS grade and used without purification,
unless otherwise noted. All reactions were run under an argon atmosphere. Water was distilled
water obtained from laboratory tap. Full synthesis experimental details can be found in Chapter
VI: Synthesis Experimental.
Variable-Temperature NMR Experiment.53 For 1H NMR experiments 31G12 was dried in
vacuo for several days before sample preparation. A sample was prepared by dissolving
approximately 3 mg in CDCl3. Variable-temperature NMR measurements were performed on an
Agilent 400-MHz NMR Spectrometer.
Strains. Bacterial strains used were derived from Staphylococcus aureus 13709 (WT). Bacteria
were routinely grown in nutrient broth and nutrient agar plates at 37°C, unless otherwise
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indicated. Mutants were selected by screening on increasing concentrations of 31G12 in nutrient
broth and designated TZNB (TriaZole Nonactate Broth). S. aureus TZNP (TriaZole Nonactate
Plate) was previously isolated from 31G12 nutrient agar plates from an unknown parent strain.
Colorimetric MIC Assays. Antimicrobial susceptibility was measured according to the Clinical
and Laboratory Standards Institute’s guideline for Standard Micro-dilution broth assay using a
final inoculum of 1x105 CFU/0.1 mL in nutrient broth (Bacto)54. The MIC was defined as the
lowest concentration of visually inhibited growth monitored colormetrically using 0.3%
resazurin after 6 h of incubation at 37°C.
Turbidity MIC Assays. Overnight cultures were plated in a Corning 96-well plate using an
inoculum of 1x105 CFU/100 µL in TSB. The test compound was twofold serially diluted in
DMSO and added to each well to a final concentration of 2% DMSO, and plates were incubated
at 37°C for 18 h. The optical density of the plates was then read on a SpectraMax M5 plate
reader at a 600 nm wavelength. The MIC was defined as the lowest concentration of the drug
corresponding to the visually inhibited growth monitored.
Bacteriostatic Activity. Overnight cultures of S. aureus 13709 were used to inoculate 1 mL TSB
in culture tubes to a final inoculum of 1x106 CFU/mL. The test compounds were twofold
serially diluted in DMSO and 20 L were added to each tube to a 2% final concentration of
DMSO, and the tubes were incubated at 37C, 225 rpm for 12 h. The MIC was defined as the
lowest concentration of drug corresponding to visually inhibited growth. In order to eliminate
carry-over, 10-fold dilution series was prepared for each sample in sterile TSB, and 100 L of
these dilutions were plated on TSA and incubated overnight at 37C, after which the CFU/mL
was calculated. From the remaining test samples, 100 L were inoculated into 1 mL TSB with
no drug and grown at 37C, 225 rpm for 12 h. Penicillin served as a bactericidal drug control.
13

Mammalian Cell Toxicity. Cell culture and drug treatment. MCF7 and MCF10A, breast cancer
cells, and HEPG2, liver carcinoma cells, were obtained from ATCC (USA). All cells were
maintained in Dulbecco’s modified essential medium (DMEM) (Gibco, CA, USA) supplemented
with 10% fetal bovine serum, 100 Units/mL penicillin and 100 μg/mL streptomycin at 37˚C in a
5% CO2 atmosphere (Gibco). Compound 31G12 was prepared at 1000 μM, dissolved in suitable
media and serial diluted in 96-well assay plates (Greiner). After 24 h of growth, 10 L of 0.3%
resazurin was added to each well and the MIC was measured via fluorescence at 560 nm
excitation/ emission 590 nm using a SpectroMax M5
Results
Synthesis of 31G12
The methyl nonactate starting material for synthesis of 31G12 was obtained as previously
described.52 Briefly, nonactin and its homologue monactin were obtained from a fermentation of
Streptomyces griseus as a mixture (Figure 2.2). Methanolysis of the mixture using Rhodococcus
generated the methyl esters methyl(±)-nonactate 1 and methyl(±)-homononactate 2. The methyl
esters were then separated by column chromatography, yielding purified homologues 1 and 2.
Methyl (±)-nonactate 1 was used as the starting scaffold for 31G12.

Figure 2.2: Structure for macrocyclic ring of nonactin and homologue monactin, which yield a
mixture of methyl (±)-nonactate 1 and methyl (±)-homononactate 2 after methanolysis.
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The retrosynthetic analysis of 31G12 is shown in Figure 2.2, involving key intermediates
5, 8, and 16.

Figure 2.2: Retrosynthetic analysis in synthesis of 31G12.
Synthesis of 31G12
The first step of the synthesis of key intermediate 5 (Scheme 2.1) was tosylation of the C8 alcohol of methyl nonactate 1 yielding 2. Reaction of 2 with sodium azide yielded 3,
possessing inverted stereochemistry at C-8. Hydrolysis of the ester yielded 4 which was
subsequently converted with oxalyl chloride into acid chloride 5. Amine 8 was synthesized by
reductive amination of commercially available 6 and 7 (Scheme 2.2).

Scheme 2.1: Synthesis of key intermediate 5 from starting material methyl nonactate with
reaction yields reported in percent.
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Scheme 2.2: Synthesis of key intermediate 8 from commercially available 6 and 7 with reaction
yields reported in percent.

For the synthesis of 16 (Scheme 2.3), commercially available amine 9 was first Boc
protected yielding 10, followed by a Swern oxidation to yield ketone 11. A Grignard reaction
between 11 and 12 produced tertiary alcohol 13. Addition of TFA to 13 simultaneously
dehydrate and deprotect yielded alkene 14. Palladium catalyzed reduction of 14 followed by
propargylation at the amine position afforded key intermediate 16. The amide bond formation
between 4 and 9 yielded 17. The final step was Cu-catalyzed alkyne-azide cycloaddition
between 16 and 17 to afford compound 31G12.

Scheme 2.3: Synthesis of 31G12 with reaction yields indicated in percent.
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31G12 exists as two rotamers
A variable temperature 1H NMR was performed to investigate whether double signals
from the methyl groups in the NMR were due to rotamers or diastereomers. Two methyl
resonances were seen at 0.76 and 0.88 ppm with an intensity ratio of (2.5:1) (Figure 1.3 A). In
addition, two more methyl resonances were seen at 1.40 and 1.48 ppm (Figure 1.3 B). The
results showed that at increasing temperatures, the methyl peaks coalesced from two peaks for
each methyl group into one peak for each methyl group A and B. The coalescing of peaks is due
to the methyl groups existing as rotamers rather than diastereomers. The coalesced peaks return
to the initially observed patterns as the temperature is cooled (Appendix A Figure 1), further
illustrating that 31G12 exists as a mixture of two rotamers.

Figure 2.4: Two sets of methyl resonance peaks (A and B) indicated with blue arrows in the
room temperature 1H NMR of 31G12.
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Figure 2.5: Observed variable temperature 1H NMR (400 MHz) of 31G12 in DMSO-d6.

Selecting for mutants of S. aureus Resistant to 31G12
To conduct target elucidation studies with 31G12, two different strains of S. aureus were
selected for resistance to 31G12. S. aureus 13709 (WT) was used as the parent strain for
screening of 31G12 resistant mutants. The selection of S. aureus 31G12 resistant mutant TZNB
(TriaZole Nonactate Broth) was obtained by initially inoculating WT at the MIC (4 M) and
growing overnight. Each day the culture was diluted to 1x105 cfu/mL in 3 mL triplicates with an
increasing concentration of 31G12 in 2% DMSO to a final concentration of 125 µM of 31G12.
From these cultures, glycerol stocks were made and designated S. aureus TZNB.
S. aureus 31G12 resistant mutant TZNP (TriaZole Nonactate Plate) was previously
isolated by Dr. Priestley, using the same method previously described but using increasing
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concentrations of 31G12 on nutrient agar plates for screening.
Confirmation of 31G12 Resistant S. aureus TZNB and TZNP
MIC data for 31G12 are shown in Table 1.2 and indicate that both TZNB and TZNP
mutants have the same MIC values for the colormetric and turbidity assays. These MIC values
are >62 times the MIC for the WT and therefore suggest resistance of both mutants. The isolates
of TZNB and TZNP were tested for resistance against 31G12 using the colormetric resazurin
reduction assay, which is dependent on measuring active metabolism via reducing resazurin into
resorufin product (Figure 2.6)32. The color change from deep purple to pink indicates that cells
are metabolically active and therefore not affected by the presence of the drug. TZNB and
TZNP resistance to 31G12 was also tested by optically measuring the turbidity to determine the
MIC. The increase in turbidity correlates with increased resistance due to the resistant strains
being less inhibited by the presence of drug. Again, both TZNB and TZNP showed resistance to
31G12 up to 500 M (Table 2.2). From these isolates only one was selected for use in
downstream applications in target elucidation.
Table 2.2: MIC values (M) for 31G12.
S. aureus Colorimetric Optically
Wild Type
4
8
TZNB
500
500
TZNP
500
500
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Figure 2.6: Colorimetric resazurin MIC assay for the effect of 31G12 (4-500 µM) against S.
aureus after development for 5 mins (A), 30 mins (B) and 60 mins (C).

Bacteriostatic Activity of 31G12.
Compound 31G12 can be classified as a bacteriostatic antimicrobial agent against S.
aureus. When S. aureus was initially grown at varying concentrations of 31G12, the MIC
measured optically was determined to be 8 M (Figure 2.7), and when treated bacteria were subcultured into drug free media it resulted in growth of all samples (Figure 2.8). Penicillin G is a
known bactericidal antibiotic with a MIC of 15.6 g/mL (Figure 2.9), and when treated cells
were sub-cultured into drug free media resulted in no growth between 31.25-1000 g/mL (Figure
2.10). Compound 31G12 was also tested for cidality by determining if the minimum bactericidal
concentration (MBC) was no more than fourfold higher than the MIC and resulted in a 3log
reduction of the initial inoculum (Figure 2.11). It was determined that up to 125 M there was
no observable 3log reduction of the initial inoculum and this suggests that 31G12 is a
bacteriostatic, not bactericidal antimicrobial.
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Figure 2.7: MIC of 31G12 (M) against S. aureus 13709 (WT) determined optically after 12
hrs.

Figure 2.8: Observed growth of S. aureus 13709 (WT) after sub-culturing into drug free media
and grown for 12 hrs.

Figure 2.9: MIC of Penicillin G (g/mL) against S. aureus 13709 (WT) determined optically
after 12 hrs.

Figure 2.10: Observed growth of sub-cultured S. aureus 13709 (WT) after sub-culturing into
drug free media and grown for 12 hrs.
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Figure 2.11: Viable bacteria count log(CFU/mL) of S. aureus after 12-hour exposure to varying
concentrations of 31G12 compared to the initial inoculum (Inoc.) to determine MBC.
Mammalian Cytotoxicity
The half-maximal (50%) inhibitory concentration (IC50) was determined for 31G12 using
three different mammalian cell lines. As previously described, the use of resazurin to monitor
cellular respiration can be used to determine the cytotoxic effects of chemotherapeutic agents.
Screening of mammalian cell lines showed that 31G12 reduced cell viability by 50% at 22 M
and 13.65 M for the breast cell lines and 7.8 M for the liver cells (Table 2.3). This indicates
that 31G12 is moderately toxic to mammalian cells.

22

Table 2.3: Mammalian cell viability with 31G12 treatment (n=2).
Cells
IC50/M
MCF7
22.01 ± 0.7
MCF10A
13.65 ± 4.2
HEPG2
7.793 ± 1.2

Discussion
The novel antimicrobial 31G12 was synthesized in a thirteen-step synthesis and
determined to exist as a rotamer as determined by variable temperature NMR. The drug displays
bacteriostatic activity against Gram-positive S. aureus and is moderately toxic to mammalian
cells. The drug was used to select for drug-resistant S. aureus and resulted in the isolation of two
resistant strains TZNB and TZNP, which were used in downstream applications for target
elucidation.
The thirteen-step synthesis and relatively low yield to synthesize 31G12 are not ideal
when trying to bring a new drug to market. However, it was later determined that compound 15
was commercially available which eliminated five steps from the overall synthesis and allowed
for faster synthesis and higher yields of 31G12. Since the drug is not commercially available,
the ability to produce drug faster is beneficial when the stock quantity is limited, and more drug
was needed for other analyses.
Although 31G12 has only two methyl groups, four methyl resonances were observed in
the 1H NMR at room temperature in DMSO-d6, which can complicate the analysis of reaction
products. Our hypothesis was that the additional resonances were due to the presence of
rotamers at the amide bond. To investigate this hypothesis, a variable temperature 1H NMR was
performed at increasing temperatures, which allows for rotation around the amide bond. The two
doublets for methyl group B (0.75 and 0.88 ppm) and two doublets for methyl group A (1.40 and

23

1.48 ppm) are most likely due to the existence of rotamers around the amide bond present in
31G12 (Figure 2.4).
The chemical shift difference between the two doublets for methyl group A (0.08 ppm) is
smaller than that of the chemical shift difference between B (0.12 ppm). The rationale for the
larger chemical shift difference seen for methyl group B is that it is closer to the amide bond.
The rotation around the amide bond can be seen as individual peaks coalescing into a single peak
at increased temperatures. The results showed that at increasing temperatures, the methyl peaks
coalesced from four resonances into two resonances, one for A and one for B. This suggest that
these peaks are due to rotamers rather than being diastereomers. The coalesced peaks return to
the initial methyl groups peaks as the temperature is cooled (Appendix A Figure 1) further
illustrating that this compound is a mixture of two rotamers. The distinction between a
compound comprised of rotamers or diastereomers is biologically important because
diastereomers can display as two different compounds in a biological system. Drug targets are
often enantioselective towards their binding partners and differences in stereochemistry may
affect the ability of the drug to elicit its toxic effects in the cell55. Optimization of synthesis and
characterization of stereochemistry should be established early in drug development in order to
reduce time and cost.
The classical approach to target elucidation of novel antibiotics involves the
identification of a gene(s) causing a resistant phenotype by genetic or biochemical strategies
using resistant clones.56 In this study, we used S. aureus for generation of 31G12 resistant clones
through two different methods. The initial method by Dr. Priestley involved gradually
increasing concentrations of 31G12 on plates and selecting for colonies that displayed
phenotypic resistance to 31G12. The resulting strain was designated TZNP (TriaZole Nonactate
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Plate). The process was then repeated by gradually increasing the concentration of 31G12 in
liquid media to select for mutants designated as TZNB (TriaZole Nonactate Broth). This
gradient method applies maximal selection pressure and resulted in generation of highly resistant
strains which were confirmed using two different MIC assays. These assays showed that TZNB
and TZNP both had MICs that were >62 times that of the wild-type strain. However, some
considerations were taken into account when using strains TZNP and TZNB for downstream
application in target elucidation. Firstly, TZNB was generated directly from reference strain S.
aureus 13709 but the reference strain for TZNP was unknown. This information is critical for
bioinformatic approaches to identify single nucleotide polymorphisms (SNPs) from whole
genome sequencing that could contribute to resistance. Secondly, by using a gradual gradient for
isolation, an increased number of mutations other than those responsible for conferring resistance
to 31G12 may have occurred. These additional mutations could be explained by selection
pressure on fitness from exposure to low levels of drug over an extended period of time, as
opposed to selecting for resistant phenotypes using an initial high concentration of drug without
a gradual gradient. An example of this is seen in the study done by Jahn et Al. using E. coli as a
model organism.57 Lastly, 31G12 has limited drug solubility in liquid and solid media. This can
be seen in Figure 2. at concentrations >62.5 M where the drug has precipitated from solution
and closely resembles growth when measuring the MIC optically. Drug solubility is important
for bioavailability, especially via oral administrations and future experiments should include
formulation to increase the solubility of 31G12 and structure based drug design studies to
improve drug solubility.58
The core structure of 31G12 is derived from the macrolide antibiotic nonactin. It was
determined that 31G12 is a bacteriostatic antibiotic. When S. aureus was initially grown in
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varying concentrations of 31G12 and then sub-cultured into drug-free media, growth was
observed in all samples, suggesting that 31G12 bacteriostatic. The result is consistent with
literature which states that bacteriostatic antibiotics prevent bacterial growth and reproduction
without killing them.59 When the antibiotic pressure is removed the bacteria will continue to
grow. This is in comparison to known bactericidal antibiotics such as Penicillin G. A
bactericidal antibiotic kills the bacteria and therefore when sub-cultured into drug-free media no
growth will occur, as seen in Figure 2.10. An antimicrobial is considered bactericidal if the
minimum bactericidal concentration (MBC) is not more than fourfold higher than the MIC and
the viable cell count results in a 3log reduction of the initial inoculum.59,60 It was observed that
growth with 31G12 results in less than a 3log reduction of the initial inoculum (Figure 2.11) at
concentrations up to fourfold the MIC, which again suggests that 31G12 is a bacteriostatic
antimicrobial.
It is important in antimicrobial drug discovery to assess mammalian cytotoxicity for a
better understanding of the pharmacological and biological characteristics of 31G12.61
Cytotoxicity of 31G12 to mammalian cells was demonstrated using three different cell lines and
31G12 was shown to have moderate toxicity. This result is important for initial screening of
drugs before in vivo efficacy, pharmacokinetic, and pharmacodynamic studies are done using
mouse models. It is also important to determine a baseline IC50 for future structure-based drug
design based on the mode of action for 31G12, which will involve decreasing the toxicity to
mammalian cells to create a more selective antimicrobial.
In conclusion, from our combinatorial library of nonactin derived antimicrobials, 31G12
was selected for further studies due to its low MIC value against Gram-positive and antibioticresistant bacteria. The synthesis and characterization indicated that 31G12 is a pure compound,
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although containing a mixture of two rotamers, and was used to select for S. aureus resistant
mutants TZNB and TZNP, which will be used in subsequent studies for target elucidation.
Compound 31G12 was determined to have bacteriostatic activity with moderate cell toxicity.
Subsequent studies were focused on finding the mode of action for 31G12.
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CHAPTER III. 31G12-BASED PHOTOAFFINITY PROBE
FOR TARGET ELUCIDATION
Introduction
Photoaffinity labeling (PAL) was first introduced in the early 1960s by Frank
Westheimer and is used to study protein-ligand interactions, elucidation of protein structures, and
identification of novel or alternative binding sites in proteins.62,63 PAL can be used in complex
mixtures, such as protein lysates, to identify target proteins to elucidate their mode of action.
The design of the photoaffinity probe should be structurally similar to the parent compound with
the exception of incorporation of a photoreactive group and alkyne tail. The most ideal PALs
would be stable in the dark at a range of pHs and display the same activity, or MICs, compared
to that of the parent compound.62
The photoreactive group of the photoaffinity probe is activated upon irradiation to form a
reactive intermediate that rapidly binds with the nearest molecule. This irreversible covalent
binding of the photoreactive group is hypothesized to occur in the same binding pocket of the
target protein as the parent compound while causing minimal damage to biological molecules
which remain intact during isolation and detection of the target protein.64 Commonly used
photoreactive groups are phenylazides, phenyldiazirines and benzophenones, which produce the
reactive intermediates of a nitrene, a carbene, and a diradical, respectively. However, the most
commonly used photoreactive group is the trifluoromethyl aryldiazirines due to its high chemical
stability and the wavelength required for activation. The diazirine is quickly converted to the
carbene intermediate upon irradiation which may minimize nonspecific binding but can also be
rapidly quenched by solvent molecules. Around 30% of the diazirine isomerizes to the diazo
derivative upon irradiation; the diazo can also decompose to the carbene, yet quite slowly.62,65
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The reporter tag of the photoaffinity probe is essential to facilitate the isolation and
visualization of target molecules. The alkyne tail of the photoaffinity probe is used to attach a
reporter tag with an azide side group via the Cu-catalyzed alkyne azide cycloaddition (“click
chemistry”). The biotin affinity tag is commonly used in PAL due to its high affinity toward
streptavidin.62 However, the interaction between biotin and avidin is the strongest non-covalent
interaction between a protein and ligand thus limiting its utility; harsh conditions are required to
break the streptavidin-biotin bonds such as those used during target protein dissociation and
elution for isolation.66,67 Other reporter tags include the use of fluorophores such as fluroscein,
BODIPY (dipyrromethene boron difluoride), rhodamine, cyanine dyes and NBD (nitrobenz-2oxa-1,3-diazole). Rhodamine is inexpensive and hydrophobic allowing it to penetrate the cell
membranes but photobleaching is a drawback to its use.
After live cells or lysates have the PAL and reporter tag attached to the target, the
samples are separated on SDS-PAGE gels and probed for labeled proteins using Western blot or
in-gel scans. Alternatively, the labeled proteins can be isolated using affinity purification and
then separated on a SDS-PAGE gel. Proteins are then excised from the gel and digested for
sequencing using MS to determine the identity of the protein. A drawback of PAL is nonspecific
cross-linking of the probe and therefore adequate controls need to be present. However, PAL
has been shown to identify off-target interactions in cells through in vitro screening which can
aid in SAR studies or identification of multiple targets within the cell as seen in Eirich et al.68
There have been many published example of the use of PAL, which demonstrates the importance
of the method in medicinal chemistry and drug discovery and highlights the wide scope of probe
designs, photophores and reporter tags62. In this study, we used 31G12 based photoaffinity
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probe JH-7-088 in conjunction with a biotin-streptavidin reporter tag for PAL, for target
elucidation of the mode action for antibiotic 31G12.

Materials and Methods
Synthesis of Photoaffinity Probe JH-7-088 and Reporter Tag JH-7-088. Complete synthesis
details can be found in Chapter VI: Synthesis Experimental.
Bacterial Strains. Staphylococcus aureus 13709 was maintained in TSB medium at 37C.
MIC Assays. Antimicrobial susceptibility was measured according to the Clinical and
Laboratory Standards Institute’s guideline for Standard Micro-dilution broth assay using a final
inoculum of 1x105 CFU/0.1 mL in nutrient broth (Bacto)54. The MIC was defined as the lowest
concentration of drug corresponding to the visually inhibited growth monitored colormetrically
using 0.3% resazurin after 6 h of incubation at 37°C.
Preparation of Proteomes. The proteomes of the bacterial strains were prepared from 50 mL
BHB media harvested after 24 h growth by centrifugation for 15 min at 10,000g. The bacterial
pellet was washed with PBS, resuspended in 5 mL PBS buffer with 5% glycerol, and lysed by
sonication with a Branson 550 sonicator under ice cooling using a cycle of 9s on/9s off, 30%
amp, for 15 minutes followed by centrifugation for 30 mins at 16,000g and concentrated using
3kDa Amicon Ultra-Centrifuge filters and stored at -20°C in 50% glycerol.
Glucose-6-Phosphate Dehydrogenase Assay. All reagents were obtained from Sigma-Aldrich.
A standard reaction mixture contained 50 mM glycylclycine, 2 mM D-glucose-6-phosphase, 0.67
mM β-nicotinamide adenine dinucleotide phosphate and 10 mM magnesium chloride at pH 7.4.
The final volume of the reaction mixture was 1.0 mL. The reaction was initiated by the addition
of 0.01 units glucose-6-phosphase dehydrogenase or 50 ng of whole cell lysate. The enzyme
activity and formation of NADPH was measured spectrophotometrically at 340 nm at 25°C.
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In Vivo Labeling Experiments. The protocol for labeling experiments adapted from Sieber68
and Taunton69. Proteomes were adjusted to a final concentration of 1.5 mg/mL by dilution in
RNase free water. Labeling was initiated by the addition of 1 µL (1 mM) probe JH-7-088 and
incubated at 25°C for 15 min. Samples were irradiated in open microwell plates for 45 min with
366 nm UV light on ice. Following incubation, 2.5 µL of 10% SDS (w/v) was added and
vigorously vortexed and then 1 µL (5mM) biotin reporter tag JH-7-022 was added immediately
followed by 2.5 µL catalyst mix (1.5 volumes 1.7 mM TBTA in 80% tert-butanol/20% DMSO,
0.5 volumes 50 mM CuSO4, and 0.5 volumes 50 mM TCEP at pH 7.0) and gently vortexed.
Samples were incubated at rt for 2 h then separated on a 4-10% gradient SDS-PAGE gel (BioRad).
Preparative Experiments. A labeling experiment was carried out at 1.5 mg/mL (500 µL) of
proteome sample as described for in vivo labeling. After click chemistry, proteins were
precipitated with acetone and stored at -20°C for 60 min prior to centrifugation (13,500g for 10
min). The precipitation was repeated twice. The pellet was air dried and rehydrated in 1% SDS
with sonication then incubated with 1 mL avidin-agarose beads (Sigma-Aldrich) for 30 min at
25°C. The beads were washed with PBS, incubated with 8M Guanidine·HCl for 15 min at 25°C,
washed three times with 500 µL PBS and buffer exchanged in 3kDa Amicon Ultra-Centrifuge
filters. Twenty microliters of 2x Laemmli buffer (Bio-Rad) was added to each sample which
was resolved on a 4-10% SDS-PAGE gel. Protein was visualized with Brilliant Blue R250.
Western Blot. Proteome samples from in vivo labeling were transferred to 0.45 µm
nitrocellulose membranes (Bio-Rad). The membranes were dried at 25°C for 3 h then blocked
overnight at 4°C in TTBS (20 mM Tris, 150 mM NaCl, 0.1% Tween 20) with 3% BSA and then
washed once with TTBS. The membrane was incubated with High Sensitivity Streptavidin:HRP
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(Pierce) at a 1:24,000 dilution in TTBS for 1 h at 25°C, then washed with TBS three times for a
duration of ten mins. Blots were detected using Amersham ECL Prime Western Blotting
Detection Reagent after incubation for 5 min at 25°C and exposed using a Fujifilm LAS-3000.
Mass Spectometry and Proteomics. Bands from the preparative experiment were excised and
sent to Alphalyse (Palo Alto, CA) for nanoLC-MS/MS and proteomic analysis. Briefly, protein
samples were reduced and alkylated with iodoacetamide and tryptically digested. The samples
were concentrated by Speed Vac lyophilization and redissolved for injection on a Acclaim
PepMap 100 C18 column (2 um) for analysis on a Dionex nano-LC system and MS/MS on a
Bruker Maxis Impact QTOF. The MS/MS spectra were used for a Mascot version 2.6.2 database
search and in-house protein database search downloaded from SwissPort 2, UniPortTRMBL, and
NCBI with a peptide mass tolerance of 10 ppm and fragment mass tolerance of 0.05 Da.

Results and Discussion
31G12 Based Photoaffinity Probes and Biological Evaluation
A 31G12-based photoaffinity probe was designed to identify and isolate proteins from S.
aureus for the target elucidation of 31G12. We initially synthesized several 31G12-based
photoaffinity probes with different structures (Figure 3.1). The first structural variation was the
addition of a benzophenone or diazirine photoreactive group, which is required to covalently
cross-link the probe to the protein target. Secondly, we varied the position of the alkyne tail
which is required to attach the reporter tag via click chemistry. The variation of probe structures
was essential to finding a modification of the original antibiotic that would be biologically active
in photoaffinity labeling experiments.
To test the modified 31G12 probes for antibiotic potency, we tested their MIC against S.
aureus WT and 31G12 resistant S. aureus TZNB and TZNP (Table 3.1). The most potent probe,
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JH-7-088, displayed the same potency in S. aureus WT as 31G12, and was selected for PAL
studies. We also synthesized a biotin reporter tag for western blot analysis and protein isolation.
This tag was also tested for activity against S. aureus WT, TZNB, and TZNP and showed no
activity (Table 3.1). This is ideal for use with the biologically active probe because the tag
should have no activity that could confound the results of the labeling experiment.

Figure 3.1: Structures of 31G12 derived Photo-Affinity Probes (JH-7-115, -088, -025) with
photo-cross-linker (green), alkyne handle (blue) and Biotin Reporter Tag (JH-7-022).
Table 3.1: MIC values (µM) for 31G12 and PALs
Compound
31G12
JH-7-022
JH-7-025
JH-7-088
JH-7-115

S. aureus WT
<8
>1000
>1000
<8
250

S. aureus TZNP
16
>1000
>1000
64
1000

S. aureus TZNB
32
>1000
>1000
64
>1000

G6PHD Assay Demonstrates Active Enzymes in Cell Lysate
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It is important in photolabeling that proteins retain their native conformations for in vitro
labeling to mitigate artificial labeling effects due to protein degradation and corresponding
changes in enzyme activity. After proteome isolation, the lysate was tested for enzyme activity
using a glucose-6-phosphate dehydrogenase (G6PDH) assay to assess the activity of known
housekeeping enzyme, glucose-6-phosphate dehydrogenase, that is present in all cells. The
protein lysate for both WT and TZNB displayed similar kinetics curves when compared to the
control (Figure 3.2) and suggesting that the proteins in the lysate were active and had retained
the native conformations. This is crucial for protein visualization and isolation in target
elucidation and determining off target effects for photoaffinity probes.
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Figure 3.2: Glucose-6-phosphate dehydrogenase (G6PDH) enzymatic assay to asses for activity
in cell lysates for S. aureus WT and TZNB compared to the control enzyme.
In vitro labeling with Photoaffinity Probe JH-7-088
To test labeling properties and establish an efficient protocol for in vitro labeling we
initially tested JH-7-088 with S. aureus WT and 31G12 resistant TZNB lysate. When using a
Western blot to visualize results, we anticipated seeing a photoaffinity labeled protein present in
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the WT lysate but absent in the TZNB lysate due to its resistance to both 31G12 and probe JH-7088. However, this hypothesis was not supported by our initial results. All protein bands were
present in both the WT and TZNB when photoaffinity labeled (Figure 3.3 A).
We sought to use the biotin-streptavidin reporter tag but, interestingly, found a strong
non-specific biotin binding protein which interferes with both the streptavidin-agarose
purification and western blot results. Initial western blot results (Figure 3.3 A) showed the strong
background band in all lanes at approximately 100 kD and the probe labeling of five other
proteins at approximately 25, 35, 50, 75 and 110 kD. These experiments were repeated using
only WT lysate because there was no difference in protein detection between WT and TZNB
lysates and to simplify the assay. The background band was present in all samples, and none of
the other previously photolabeled proteins were present, except for the 110 kD protein band
(Figure 3.3 B). This raised concern for target elucidation using a PAL system because of the
inconclusive results. Therefore, further experimentation was needed to confirm that an efficient
labeling protocol had been established, the diazirine was still intact on our probe required for
cross-linking to the protein of interest, and determining if the 110 kD band is our protein of
interest.
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Figure 3.3: Initial Western blot of initial photolabeled proteins and controls (A) compared to
repeated results (B).

BSA Controls to Establish Efficient Labeling Protocol
Due to the inconclusive results from the western blots, a biotinylated bovine serum
albumin (BSA) and a BSA with an alkyne tail were used as controls to establish an efficient
protocol for PAL. We purchased a biotinylated BSA to serve as a Western control for
visualization when using streptavidin-HRP (Figure 3.4). To determine if the biotin tag JH-7-022
was being successfully added to probe JH-7-088 via click chemistry, we created a BSA with an
alkyne tail (BSA-Alkyne) (Figure 3.4). These BSA controls were spiked into the lysate which
underwent the photolabeling protocol. The background band from the lysate and the BSAalkyne and biotinylated BSA bands at 66.4 kD were present on the western, indicating that our
tag JH-7-022 was being successfully added via click chemistry to the BSA and probe, and that an
efficient labeling protocol had been established.

36

Figure 3.4: Western blot of BSA controls to establish an efficient labeling protocol.
UV/VIS Measurement of Probe Diazirine Activation
To determine the chemical stability of the diazirine in probe JH-7-088, we used
photolysis in methanol for a fixed period of time and followed the diazirine activation
spectrophotometrically. The diazirine showed an absorbance peak at 350 nm (Figure 3.5 D),
which is consistent with other 3-trifluoro-methyl-3-aryldiazirines spectral properties.65,70–72
Upon irradiation the peak at 350 nm, decreases which indicates the conversion of the diazirine
into other species. The peak at ~270 nm increases with irradiation time due to the rearrangement
of the diazirine into its isomer (Figure 3.5 A → B). The conversion of the diazo into the carbene
is relatively slow and can be monitored spectrophotometrically (Figure 2.5 B → C).72 Together
these results indicate that the diazirine was still present on the probe and therefore should be
generating the carbene and therefore covalently cross-linking to protein(s) in our PAL protocol.

Figure 3.5: UV-Vis spectral changes that occurred upon irradiation of diazirine PAL JH-7-088
(A) in methanol converting in its isomer (B) and carbine (C). Insert (D) shows the absorbance
changes between 330-390 nm, as a function of irradiation time for the diazirine conversion into
its isomer.
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Evaluation of Potential Photoaffinity Labeled Protein Target
In order to optimize the probe concentration and determine specific photoaffinity labeled
proteins in vivo, the lysate was treated with varying concentrations of JH-7-088. The initial
western blot showed a strong dose dependence for all labeled proteins while the background
band at 100 kDa remains relatively the same in all samples (Figure 3.3). Again, when the
experiment was repeated the protein bands below the 100 kDa background protein band failed to
be detected (Figure 3.6). Using ImageJ to measure densitometry of the 110 kDa protein band in
the repeated experiments, shows a dose dependence curve (Figure 3.7). This suggest that the
target protein may correspond to this protein band at 110 kDa.

Figure 3.6: Labeling of cell lysate by concentration-dependence using JH-7-088 of the initial
western blot (A) and repeated results (B).
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Figure 3.7: Densitometry measurements of the 110 kDa band from the repeated western shows
a strong does-response to increasing concentrations of JH-7-088 PAL.

To test the hypothesis that the 110 kDa protein was the target, we pre-treated the lysate
with 31G12 prior to photoaffinity labeling with JH-7-088. Compound 31G12 should bind
preferentially to the binding site of the target protein and therefore not allow JH-7-088 to bind.
The western blot and densitometry analysis (Figure 3.8) showed that there was a ten-fold
decrease in relative density in the samples pre-treated with 31G12 prior to labeling. This
evidence also supports the hypothesis that our target protein corresponds to the 110 kDa band
seen in the western blots.

Figure 3.8: Competitive, concentration-dependent displacement of JH-7-088 by antibiotic
31G12 in labeling experiments via western blot (A) using cell lysate and densitometry
measurements (B).
Preliminary Results
Since the potential target protein at 110 kDa is very close to the biotinylated background
protein band at 100 kDa, isolation and visualization was difficult in PAL experiments.
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Therefore, an alternative tag, Azide-fluor 545 (5-carboxytetramethylrhodamine-azide), was used
instead of the biotin-streptavidin reporter tag. Azide-fluor 545 is a fluorescence based
rhodamine tag, which can be visualized by scanning fluorimetry of SDS-PAGE gels. This
approach eliminates the use of Western blots for protein visualization. Like the biotin tag JH-7022, this tag also has an azide side chain used to attach to the probe via click chemistry. The
preliminary results showed multiple bands (Figure 3.9) being labeled in both the probe and no
probe samples. However, a band does appear at approximately 100 kDa in the probe sample as
seen in the previous western blots. This band was absent from the no probe and 31G12 pretreated samples. BSA-alkyne was used again as a click chemistry control and showed both the
monomer at (66 kDa) and the dimer (132 kDa) being successfully labeled with the azide-fluor
545 tag. This suggests that we have established an efficient protocol for labeling proteins using
the rhodamine tag and the protein at ~100 kDa is our target protein and possible target for
31G12.

40

Figure 3.9: Photoaffinity labeleing of S. aureus WT lysate using probe JH-7-088 tagged with
azide-fluor 545 and BSA-alkyne-azide-fluro 545 controls.
Preparative Scale PAL for LC-MS/MS Data Analysis
Based on the western blot results, we hypothesize that the target protein is going to be at
the relative molecular mass in the SDS-PAGE gel as the background band after protein isolation
using streptavidin-agarose, which correlates to the proteins seen at both 60 and 100 kDa. The
SDS-PAGE gel shows three different bands of interest at around 37, 60, and 100 kDa with the
biotinylated background proteins at approximately 60 and 100 kDa (Figure 3.10). Interestingly,
the proteins seen at 37 and 60 kDa correspond to the initial western where these bands were also
present. However, these bands were not reproducible on subsequent experiments. The band at
60 kDa was excised and sent to Alphalyse for multiple protein analysis via nanoLC-MS/MS.
This protein band was chosen based on the fact that it was isolated from streptavidin-agarose
beads, which indicates that these proteins were successfully labeled with probe JH-7-088.

A

B C

D

E

100 kD
75 kD
50 kD
37 kD
25 kD

Figure 3.10: Labeling of S. aureus WT and TZNB preparative experiment. Protein sample after
click chemistry (A), protein precipitation and pellet rehydration (B), cell lysate (C), non-specific
binding to avidin-agarose (D) and recovered labeled proteins (E).
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Protein Identification via nanoLC-MS/MS
To determine if the protein of interested isolated from the preparative scale PAL is
present compared to that of the background proteins, we did a comparative analysis of the MSMS spectra between results. The MS-MS spectra results from the protein were used in Mascot
database search to identify similar proteins based on their peptide sequence and fragment mass to
charge ratios. The results were scored using a probability-scoring algorithm and the best
matches were reported as results. A positive identification was reported when two peptides have
an Ions score above 35 or if a protein under 20 kDa has one peptide with an Ions score above 50.
The reported results from Alphalyse indicated that there were 15 S. aureus proteins within the 60
kDa PAL band (Table 3.2). The background band was also sent to Alphalyse for protein
identification and resulted in only one similar protein, the catalase protein, as the PAL analysis.
Expected results were that the background analysis and PAL analysis would share more similar
proteins and comparative analysis between results would narrow down the potential target
proteins.
Table 3.2: List of protein identified and calculated molecular weight by nanoLC-MS/MS
peptide sequencing and database search.
Protein Name
Calculated MW (kDa)
Elongation factor
43.1
Enolase
47.1
Dihydrolipoyl dehydrogenase
49.5
Formate-tetrahydrofolate ligase
49.5
Glutamine synthetase
51
2,3-biphosphoglucerate-dependent phosphoglycerate mutase
26.7
Glutamyl-tRNA(Gln) amidotransferase subunit A
52.9
Pyruvate kinase
63.2
1-pyrroline-5-carboxylate dehydrogenase
57
Catalase
58.3
Phosphoenolpyruvate carboxykinase
59.5
Ferritin
19.6
Inosine-5~monophosphate dehydrogenase
52.9
L-lactate dehydrogenase
34.5
30S ribosomal protein S5
17.7
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Limitations and Future Directions
Currently, we have identified a potential target protein of the PAL assay to be at
approximately 110 kDa, but further analysis is required for specific protein identification and
target elucidation of 31G12. Future experiments using azide-fluor 545 instead of biotinstreptavidin will include a does-dependent response, competitive 31G12 displacement and
preparative scale protein isolation for LC-MS/MS analysis to further elucidate the protein of
interest and mode of action for 31G12 by photolabeleing.
A limitation of using the LC-MS/MS for protein identification in PAL is that the probe is
covalently attached to our protein of interest. If this is true, the probe would add 1.092 kDa to
the peptide fragment of the protein of interest and produce a different spectra. This difference in
spectra would not be recognizable by a MASCOT database search and could possibly give false
positive results. We plan to mitigate this problem with two different approaches. The first is by
synthesizing a probe with an alanine residue attached to use as a standard in LC-MS/MS
experiments. This will allow us to extract the spectral differences between Alanine and Alanine
with the probe JH-7-088 attached. These data are then used to search the raw spectral data from
Alphalyse to find a spectra similar to the probe and use this to identify the protein of interest.
The second approach is to write a computer program that will scan through the spectra of both
the background and PAL sample and extract the spectra that are not similar to one another. This
should provide us with the spectra to use for protein identification.
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CHAPTER IV. A BIOINFORMATIC APPROACH TO
TARGET ELUCIDATION OF 31G12
Introduction
The search for new antibiotics with novel mechanisms of action remains a significant
challenge to combat resistance to existing antibacterial therapies.73,74 Drug resistance is encoded
in the bacterial genome through resistance-associated mutations or single-nucleotide
polymorphisms (SNPs) and can serve as biomarkers in bacterial drug resistance profiles.75
Besides SNPs that contribute to drug resistance in genes that encode for the protein target or
drug-metabolizing enzyme, there are three other classes of genes that may confer a selective
advantage against antimicrobials.75 First, decreased permeability of membrane barriers or
membrane-associated efflux systems can minimize exposure to the drug.76 Secondly,
compensatory mutations can offset the fitness costs of the initial mutation that confers
resistance.77 Third, bacteria with increased mutation rates can increase the rate at which
beneficial mutations can occur in the presence of drug treatment providing a selective
advantage.78 Much effort has been made to identify candidate SNPs that give rise to molecular
variants causing phenotypes, such as those associated with drug resistance, using databases and
web resources.79 Over the past decade, bioinformatic research has led to a better understanding
of the effects of these molecular variants.79
We investigated the use of genome sequencing and genome-wide association studies
(GWAS) to identify SNPs and genes associated with resistance to 31G12 using an all-bacterial
bioinformatics resource center, Pathosystems Resource Integration Center (PATRIC). PATRIC
is an online resource that stores and integrates data such as genomics, transcriptomics, protein44

protein interaction, 3D protein structures, sequence typing data and associated metadata.80 For
utilization in comparative genomic analysis there are over 80,000 bacterial genomes which
includes more than 6,000 antibiotic resistant genomes (as of August 2016). Genome assembly
using Assembly RAST assembles short reads that are single or paired-end (Illumina) and long
reads from filtered FASTQ files (PacBio) using base calling algorithms such as BayesHammer
or Kmergeni and assembler such as Velvet, IDBA, Spades, MEGAHIT and MiniASM (Figure
4.1). A custom ARAST is used to evaluate and score the assemblies and frameworks.

Figure 4.1: The various assembly strategies offered in PATRIC (reference).

RAST tool kit (RASTtk) is used for genome annotation which allows for comparative
analyses of all genomes in PATRIC because they are processed identically so that comparisons
can be made. PATRIC also offers a proteome comparison service that aligns multiple genomes
to a reference genome in a bidirectional best BLASTP analysis.
The most useful tool for our investigation to identify SNPs is the use of the variation
analysis service. Here multiple short or long read files are aligned against a reference genome to
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which variation such as SNPS, Multiple Nucleotide Polymorphism (MNPs), insertions, and
deletion with confidence scores and polymorphisms are reported. The variation analysis can be
performed using different aligner programs such as BWA-mem and BWA-mem-strick, Bowtie,
MOSAIK and LAST with variant caller algorithms FreeBayes and SAMtools.80 The variant
prediction can lead to false positives due to sequencing errors and misplacement during
alignment but can be partially reduced by quality filtering.81–83 The high-quality genetic variants
reported by PATRIC for 31G12 drug-resistant strain TZNB were then screened for resistance
using traditional laboratory techniques to assess whether these biomarkers actually contribute to
drug resistance and therefore provide the mode of action for 31G12.
Materials and Methods
Strains. Bacterial strains were derived from Staphylococcus aureus 13709 (WT). Bacteria were
routinely grown in nutrient broth and nutrient agar plates at 37°C, unless indicated otherwise.
Isolates were selected by screening on increasing concentrations of 31G12 in nutrient broth
(TZNB). S. aureus TZNP was previously isolated from 31G12 nutrient agar plates from an
unknown reference strain. Parental reference strain S. aureus 55/2053 genome was publicly
available from NCBI.
DNA Extraction and Sequencing. S. aureus strains were cultured in tryptic soy broth (Bacto) at
37°C with shaking overnight. Chromosomal DNA purification methods were adapted from
those provided by Dr. Horswill, University of Colorado School of Medicine (Aurora, CO), using
the Qiagen PureGene Yeast/Bact. Kit B. Lysostaphin from Staphylococcus simulans was
purchased from Sigma-Aldrich. Genomic DNA from WT and TZNB was sent to Washington
State University Laboratory of Biotechnology and Bioanalysis (Pullman, WA) for library
preparation, sequencing and assembly, using 60x coverage with a single SMRTCell by PacBio.
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S. aureus TZNP was sent to University of Montana Genomics Core for library preparation
(Nextera DNA library prep kit, Illumina) and Illumina MiSeq sequencing using 60x coverage.
Genome Assembly and Annotation. “Meta-service” comprehensive genome analysis service
including assembly and annotation was done using the PATRIC Bacterial Bioinformatics
Resource Center as follows. BayesHammer was run on S. aureus WT and TZNB reads and
assembled using MiniASM. ARAST was used to sort assemblies and calculate quality score
reads. BayesHammer was run on S. aureus TZNP and the sequence was assembled using Velvet,
IDBA and Spades after which assemblies were sorted and scored using ARAST. All genome
annotations were done using RASTtk.
Variation Analysis. Single-nucleotide polymorphism (SNP) calling was done using the
PATRIC Bacterial Bioinformatics Resource Center as follows. Paired read libraries (FASTQ
files) were used to align to a reference genome using BWA-mem and SNPs were called using
FreeBayes.
Bacterial strains and plasmids. Strains and plasmids used in this work are listed in Appendix A
Table 1. Escherichia coli was grown in Luria-Bertani broth or on Luria agar plates and
supplemented with ampicillin (100 μg/mL) for the maintenance of plasmids and S. aureus was
grown in TSB or on TSA and supplemented with chloramphenicol (7 μg/mL) for the
maintenance of plasmids. pCM29 was provided by Dr. Alexander Horswill (Department of
Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA).
Bacteria were grown overnight at 37°C with shaking at 225 rpm.
Mutant library constructs. Each of the high-quality variants was amplified using primers
generated from sequencing data of S. aureus TZNB and joined by overlap PCR extension using
genomic DNA from S. aureus TZNB as a template. PCR products were ligated with T4 DNA
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ligase (Invitrogen) into pCM29 at the SacI and KpnI sites and electroporated into chemically
competent TOP10F´ E. coli and screened for plasmids via colony PCR. Plasmid DNA was
purified from these strains using the Qiagen Plasmid Kit-tip 20 (Qiagen), and then inteoduced by
electroporation into S. aureus RN4220. Plasmid DNA from S. aureus RN4220 strains was
purified using the Qiagen Plasmid Kit-tip 20 and sequenced for mutation confirmation
(Genewiz). A list of primers, strains and a map of pCM29 used in this study are listed in
Appendix A, Table 2 and Figure 3.
31G12 resistance assay. S. aureus strains were grown overnight in TSB at 37°C with shaking at
225 rpm. Those with pCM29 were supplemented with 7 µg/mL chloramphenicol to maintain the
plasmid. Cultures were plated in triplicate in 96-well microtiter plates at 1x105 cfu/100 µL in the
presence of 31G12 and incubated at 37°C for 18 h. Plates were visualized at 600 nm on a
SpectraMax M5 microplate reader to determine turbidity.
Results
Whole-genome sequencing and annotation statistics.
To identify genes that might contribute to 31G12 resistance, we sequenced and annotated
the genomes of the susceptible parental strain S. aureus 13709 (WT), and two drug-resistant
clones TZNB and TZNP. Parental strain S. aureus 55/2053 for TZNP was publicly available via
NCBI. The whole-genome sequence statistics of the two drug-resistant clones compared to the
parental stains are shown in Table 4.1. The sequencing depth was 60x, and read mapping results
indicated nearly complete genome coverage for TZNB (96.90%) with only 159 (0.005%) of
bases with zero coverage and good genome coverage for TZNP (91.96%) with 327847
(10.925%) bases with zero coverage. This suggested that the genomes of drug-resistant strains
were closely related to their parental strains and could be used in further bioinformatic analysis
to determine SNPs that may contribute to resistance.
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Table 4.1: Statistics for whole-genome sequencing of the 31G12-resistant strains TZNB and
TZNP compared their respective parent strains S. aureus 13709 WT and 55/2053.

TZNB

TZNP

Parent Strain

WT 13709

55/2053

Total Reads

119356

10908694

115661 (96.90%)

10032000 (91.96%)

Total reference bases

3000992

2756919

Median base coverage

143

472

140.5

487.7

Bases with zero coverage

159 (0.005%)

327847 (10.925%)

Bases with <=10 coverage

21662 (0.722%), in 5614
contiguous regions

343314 (11.440%), in 3206
contiguous regions

Genome Statistics

Properly Mapped Read

Mean base coverage

Proteome Comparisons
In order to directly compare the proteomes of drug-resistant strains compared to parental
strains, proteomic profiling was done using Sequence-based Comparison tool that was part of
RAST. The circle plot shows the whole-genome schematic colored by BLAST similarity
between compared strains (Figure 4.2 A and B). The changes in similarity relative to the
reference genome goes from blue representing the highest protein sequence similarity to red
representing the lowest. Analysis of the data table (data not shown) from the proteome profiling
showed that 22 proteins from TZNB shared less than 100% identity when compared to the
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reference genome WT 13709, resulting in 0.75% changes in conservation and 85 proteins from
TZNP share less than 100% identity when compared to the reference genome 55/2053, resulting
in 3.24% changes in conservation.

Figure 4.2: Proteomic profiling comparisons between parental strains and drug-resistant strains;
WT and TZNB (A) and TZNP and 55/2053 (B).
Identification of high-quality SNPs reported in PATRIC variation analysis.
To identify genetic variants that may be involved in drug resistance, the variation analysis
using BWA-mem and FreeBayes in PATRIC was used and yielded multiple SNPs between the
parental strains and drug-resistant strains. The high-quality SNP variants for each comparative
analysis between the four different genomes are presented in Figure 4.3.
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Figure 4.3: The high-quality SNP variants reported using PATRIC variation analysis. The tails
of the arrow represent the input files and the heads represent the reference genome for each
analysis. The number over the arrow represents the number of SNP variants called between that
analysis.

As a reference point for probability scores reported by PATRIC in the variation analysis,
the WT genome was assembled using two different assembly algorithms, PacBio’s Hierarchical
Genome Assembly Process (HGAP) and PATRIC’s BWA assembly, and used with FreeBayes
variant analysis. By using two different assemblers there were 14 SNPs called between genomes
with scoring between 11.03-15.61. The probability scores indicate the likelihood that the SNP
has occurred within the genome, and therefore these low scores indicated that the SNP is not
likely to occur.
Identifying six potential proteins that confer resistance to 31G12.
To generate a list of possible protein targets from the variation analysis, the parental
strain WT and drug-resistant strain TZNB were used to narrow down potential proteins of
interest. From the 1971 raw FreeBayes variants called between TZNP and parent strain WT only
23 high-quality variants were reported (Table 4.2). The SNPs called were 1 synonymous, 20
51

non-homologous and 2 unidentified. From the remaining non-homologous SNPs, all proteins
annotated as phage, hypothetical proteins or less than 20 kDa were removed. This filtered the 23
high-quality variants to six high-quality variants and therefore six possible target proteins that
confer resistance, hereafter referred to as the six potential proteins (Table 4.3).
Table 4.2: The 23 high-quality variants in S. aureus TZNB compared to reference genome S.
aureus WT.
Genome
position

Putative gene product and function

Amino Acid change
S. aureus
WT

568

Deletion

1207

Phage-associated homing endonuclease

1819

Phage protein

G

2234

Phage protein

DY

Q

*

Nonsyn
Deletion

D

3116
3167

Polymorphism

S. aureus
TZNB

Deletion
Insertion

hypothetical protein

QN

HE

Insertion

3643

Ribosomal protein L11 methyltransferase (EC 2.1.1.-)

GV

GC

Insertion

13384

Replication protein

EKN

EK

Deletion

3490

14388

Deletion

14610

Deletion

15318

hypothetical protein

FY

F

Deletion

16555

Transcriptional regulator, LysR family

GS

G

Deletion

62291

GKNI

GKKY

Insertion

63292

Lead, cadmium, zinc and mercury transporting ATPase
(EC 3.6.3.3) (EC 3.6.3.5)
Multicopper oxidase

PKKI

PKKD

Insertion

64310

Multicopper oxidase

QF

QF

Insertion

65122

Transposase, IS4 family

IK

I-

Insertion

DNA-directed RNA polymerase alpha subunit (EC
2.7.7.6)
Phosphoserine phosphatase (EC 3.1.3.3)

L

*

Nonsyn

QKI

QK*

Insertion

T

T

Synon

2225863

ABC-type dipeptide/oligopeptide/nickel transport system,
ATP-binding protein
FIG00002411: Thioredoxin-fold protein

S

F

Nonsyn

2621562

DNA-directed RNA polymerase beta subunit (EC 2.7.7.6)

PK

QK

Nonsyn

2894249

Phage protein

NKNN

NKKQ

Insertion

2898237

Structural protein, phage associated

QW

H

Deletion

66535
885721
1450988
1823787

*, truncation
-, insertion.
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Table 4.3: Six potential proteins filtered from the 23 high-quality variants in S. aureus TZNB
compared to reference genome S. aureus WT 13709. Predicted protein size was generated using
amino acid sequences obtained from PATRIC in ExPASy.
Genome
position

Putative gene product and
function
Ribosomal protein L11
methyltransferase
Transcriptional regulator, LysR
family
Lead, cadmium, zinc and mercury
transporting ATPase
DNA-directed RNA polymerase
alpha subunit

3643
16555
62291
885721
1450988

Phosphoserine phosphatase

2225863
Thioredoxin-fold protein
*, truncation.

Amino acid change
S. aureus WT
TZNB

Polymorphism

Predicted
Protein Size
(kD)

PATRIC
Score

GV

GC

Insertion

35.54

13.28

GS

G

Deletion

33.79

20.06

GKNI

GKKY

Insertion

86.7

14.22

L

*

Nonsyn

34.37

927.80

QKI

QK*

Insertion

38.26

180.65

S

F

Nonsyn

31.31

880.34

Identification of synonymous proteins in the comparative variation analysis of the resistant
strains compared to the sensitive strain.
A comparison of SNP variants called between drug-resistant strains and parental strains
was used to identify synonymous proteins identified in the variation analysis to determine the
protein(s) potentially responsible for resistance to 31G12. These six potential proteins, and
reported SNPs, were used to cross-reference all other high-quality variants called in independent
variation analysis to look for a homologous SNP or protein.
The reverse variation analysis of TZNB and parental strain WT (i.e. WT was compared to
the reference strains TZNB) reported 41 high-quality variants (Figure 4.3). From these 41 highquality variants three proteins, thioredoxin-fold protein, DNA-directed RNA polymerase alpha
subunit, and phosphoserine phosphatase, were all reported with the same SNPs as that of the six
potential proteins.
In the variation analysis between TZNP and reference genome WT there were 36,686
high-quality variants reported (Figure 4.3). From these variants, the six potential proteins were
reported with both synonymous and non-synonymous SNPs, but there was not an identical SNP
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reported. From the 184 high-quality variants reported between TZNP and parental strain
55/2053, none of the six potential proteins was reported (Figure 4.3). However, the DNAdirected RNA polymerase beta subunit was reported to have a non-synonymous SNP. This
protein is part of the DNA-directed RNA polymerase called in the six potential proteins, but the
SNP was reported in a different subunit.
Protein alignments indicated presence or absence of SNPs in the six potential proteins.
The six potential proteins had amino acid changes based on the protein alignment of
drug-resistant strains TZNB and TZNP compared to WT 13709 strain (Table 4.4). These
predicted results suggest the likelihood that the non-synonymous SNPs called in the variation
analysis may be present or absent in the genomes of drug-resistant TNZB and TZNP. The full
protein alignments are available in Appendix A Figure 2.
Table 4.4: Predicted amino acid changes in the six potential proteins from drug-resistant TZNB
and TZNP compared to WT 13709 strain.
Gene Product
TZNB
TZNP
Ribosomal protein L11
D36Y, M71L, Q94H, H192Y,
methyltransferase
E257D
Transcriptional regulatory, LysR family
P181S, T241K, D244N, S270N
Lead, cadmium, zinc and mercury
K144R, I315V, N317D,
transporting ATPase(1)
R504C, V577M, S648N,
A676T
Lead, cadmium, zinc and mercury
(No homologue)
transporting ATPase(2)
DNA-directed RNA polymerase alpha
L310*
subunit
Phosphoserine phosphatase
Q107R, K109E, L122I, I156T,
I334*
T165N, Y295N, N298K, L376*
Thioredoxin-fold protein
F30S
V95L
DNA-directed RNA polymerase beta
E355D, P614Q, Y737F
subunit
*, indicates truncation.
-, indicates no mutation observed.
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Confirmation of SNPs in six potential proteins of TZNB in gene clones.
To test whether the potential SNPs identified by the variation analysis actually occurred
and conferred resistance to 31G12, each high-quality variant from TZNB was cloned into vector
pCM29 and expressed in sensitive strain RN4220. The expression system was validated in the
selected transformants by PCR and sequencing. Sequence analysis of the transformants
confirmed that only two of the predicted SNPs occurred in drug-resistant strain TZNB. The
phosphoserine phosphatase was prematurely truncated due to experimental error and resulted in
truncation of 36 amino acids (Table 4.5).

Table 4.5: Confirmed amino acid mutations of TZNB compared to parental strain WT 13709.
Gene Product
TZNB
DNA-directed RNA polymerase alpha subunit
L310*
Phosphoserine phosphatase
T341*
Thioredoxin-fold protein
F30S
*, indicates truncation.

Susceptibility of the TZNB mutants to 31G12.
The susceptibility of the generated TZNB mutants to 31G12 was assessed based on dose
response inhibition. Although only two proteins had confirmed mutations, all variants were
cloned into vector pCM29 under control of the sarA promoter to produce high expression levels
when transformed into host strain RN4220. The EC50, which is the concentration of 31G12 that
gives half-maximal response, was determined for each mutant and compared to RN4220 (host),
vector alone and TZNB (Table 4.6). The drug-resistant TZNB had an EC50 of 23±3.1 µM, which
was a two-fold increase in EC50 compared to the host (11.2±2.3), vector control (9.276±1.8) and
WT (9.644 ± 1.4). All mutants fell within the range of the controls and exhibited sensitivity to
31G12 (Table 4.6). The EC50 from the growth inhibition of each transformed mutant did not
exhibit resistance to 31G12 compared to that of WT, host, vector control and TZNB.
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Table 4.6: Sensitivity of S. aureus 31G12 sensitive strains (WT, Host, Vector Only), drugresistant strain TZNB and mutants to 31G12.
Strain or mutant
EC50 (µM)
WT 13709
9.644 ± 1.4
TZNB
23.07 ± 3.1
Host (RN4220)
11.2 ± 2.3
Vector Control
9.276 ± 1.8
Phosphoserine Phosphatase
10.73 ± 1.8
DNA-Directed RNA Polymerase alpha subunit
10.21 ± 1.5
DNA-Directed RNA Polymerase beta subunit
10.41 ± 2.3
Lead, Cadmium, Zinc and Mercury ATPase (1)
10.64 ± 1.6
Lead, Cadmium, Zinc and Mercury ATPase (2)
9.519 ± 2.1
Transcriptional Regulator, LysR
8.818 ± 1.6
Ribosomal Protein L11 Methyltransferase
11.58 ± 1.5
Thioredoxin-fold Protein
11.28 ± 1.8

The percent maximum growth for the thioredoxin-fold protein mutant was found to be
higher than that of the percent maximum growth of the host and vector control between 31G12
concentrations 2-16 µM (log10 µM range 0.301-1.004) and the L11 methyltransferase was found
to be higher than controls at 8µM (Figure 4.4). All other mutants exhibited maximum growth at
or below the levels of host and vector controls (Figure 4.4). These results suggest that the high
expression levels of the thioredoxin-fold protein and L11 methyltransferase may provide a
fitness advantage at sub-inhibitory concentrations of 31G12.
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Figure 4.4: Dose response curves of each transformed mutant compared to drug-resistant TZNB
and sensitive strains RN4220 (host) and RN4220/pCM29 (vector control) with error bars
representing the standard error of the mean (SEM) of triplicate samples.
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Discussion
To identify genetic markers of drug resistance to 31G12, we performed whole-genome
sequencing of S. aureus WT, TZB, TZNP. These genomes and publicly available genomes were
used in PATRIC for variation analysis to identify SNPs that could contribute to resistance.
Unlike other bioinformatics software, PATRIC does not require
that the user have prior computer programming experience.
However, additional background information on the algorithms
implemented in each program does contribute to a better
understanding of the probability scoring and evaluations of
high-quality variants reported.
Selection of a proper alignment algorithm to be used in
the variation analysis is important when using long reads, such
as those produced by PacBio sequencing, or if the reads contain
indels. The Burrows-Wheeler Alignment (BWA) is a sequence
alignment package that is based on the backward search with
Burrows-Wheeler Transform for mapping low-divergent

Figure 4.5: The workflow for
variation analysis to determine
genetic SNPs.

sequences against a large reference genome.82 This algorithm allows for gapped alignment for
single-end reads, supports paired-end mapping, generates mapping quality and gives multiple
hits if required.82 For the variation analysis the BWA-mem aligner was selected because it can
be used for mapping short reads, such as those from the TZNP Illumina sequencing, or long
query sequences obtained from the PacBio sequencing of WT 13709 and TZNB (Figure 4.5). To
use this algorithm in PATIC, the user inputs the raw FASTQ files from sequencing to be
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compared against a fully assembled reference genome, to generate an output alignment file in a
SAM format, which can be used in other downstream analysis.
These SAM file alignments are then used in FreeBayes to detect genomic variants within
the alignment (Figure 4.5). FreeBayes indicates the number of raw read variants determined
from the variation analysis and use a Baysian model to further refine the results to report only the
high-quality variants. The variation summary indicates how well each of the input FASTQ files
are properly mapped to the reference genome and the coverage of bases. Drug-resistant strain
TZNB was derived from WT 13709, and as expected we see a high percentage of properly
mapped reads (96.9%) with only 0.005% of bases with zero coverage. This indicates that the
two are closely related and a good match when looking for variations called between the two
genomes.
As previously mentioned, the original parent strain of TZNP was unknown and therefore
when TZNP is compared to the WT strain there is a much lower percentage of properly mapped
reads (89.58%) and a higher percent of bases with zero coverage (10.925%). This is not ideal
when trying to identify SNPs that could contribute to resistance because of the low match
between the two genomes. To find a more similar parental strain to use as a reference genome
for variations analysis of TZNP, the whole genome was imported into BLASTn. S. aureus
55/2053 was selected for analysis in this study as a new reference genome for TZNP because it
had the highest percent match (100%) and lowest e score (0.0) reported in BLASTn. When
using 55/2053 as a reference genome for TZNP, the properly mapped reads increased to 91.96%,
however there was still 10.925% of bases with zero coverage, which could be due to sequencing
errors. This indicated that the genomes of 55/2053 and TZNP are more closely related and a
better match for determining SNP variants that could confer resistance to 31G12.
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This high similarity between genomes in drug-resistant strains and their respective parent
genomes was also illustrated in the high protein sequence identity determined in the proteome
profiling. This again illustrates the low changes in conservation of the genomes and suggest that
they are good matches for SNP variant analysis.
By using the variation analysis of WT 13709 when compared to itself, a reference point
for the scoring of likelihood variants reported was established. The fourteen SNPs reported were
due to the use of two different assemblers to create a reference genome for the variation analysis.
As expected, the likelihood scores reported are low (11.03-15.61) because the input genome was
the same as the reference genome, except for the use of two different assemblers. Therefore, in
other variation analyses a likelihood score reported that is close to that of the reference point
scoring can be expected to occur less likely in the genome.
The list of six potential proteins was used to search for similar proteins in the other
variation analysis because TZNB was derived from WT 13709 and therefore provided the best
comparison between genomes to identify SNPs that could contribute to drug-resistance of
31G12. When filtering the non-homologous SNPs reported between TZNB and WT 13709, we
applied a 20 kDa protein size cutoff based on our previous work to elucidate the target protein
through a 31G12-based photoaffinity assay. The western blots indicated that no proteins below
20 kDa were being labeled. However, in applying this filter, three proteins were removed from
the list of potential proteins, but the likelihood scores were in the same range as the reference
point scores and therefore disregarded. It was very unlikely that 31G12 target protein was a
phage protein and therefore we removed four of these proteins from our potential list and those
proteins reported as hypothetical or no function were also disregarded due to the low likelihood
that these could theoretically be our target and mode of action.
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The next objective was to conduct a comparative analysis using the six potential proteins
to search for a protein that is shared between TZNB and TZNP from all the variation analysis
that could be identified as the target protein and mode of action for 31G12. It is not surprising
that the thioredoxin-fold protein, RNA-dependent DNA polymerase alpha subunit and
phosphoserine phosphatase was reported in the reverse variation analysis between TZNB and
WT 13709 due to their large likelihood scores. From the 36,686 SNPs reported in the variation
analysis between TZNP and WT 13709, it was also not surprising that five of the six potential
proteins, apart from the lead, cadmium, zinc and mercury ATPase (2), were reported with
various synonymous and non-synonymous SNPs because the two strains are not very similar to
one another. Although TZNB and TZNP share five similar proteins with variants reported it was
surprising that there was not an identical SNP reported within these five proteins. By using
55/2053 as a reference genome for TZNP instead of WT 13709, it decreased the number of highquality variants reported from 36,686 to 184. This was expected due to the high similarity
between the two genomes, however it was unexpected that none of the six potential proteins was
reported. One explanation for these results is that 31G12 is targeting two different proteins
causing two separate SNPs or are there different SNPs within the same protein conferring
resistance. Another alternative explanation is that the drug is being extruded from the cell by
way of an efflux pump and did not select for a SNP, which is why no mutation would be found
conferring resistance through the bioinformatics approach of target elucidation.
Although our bioinformatics results did not produce a single protein with an identical
SNP, each of the six potential proteins from TZNB weas screened for resistance against 31G12.
The sarA promoter in pCM29 produces high expression levels of the cloned gene when
transformed into host RN4220. However, the host gene product is still being produced by the
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cells. This approach of cloning by exploitation of gene dosage effects has been widely used
based on the principle that by increasing the number of copies of a given gene can lead to
increased synthesis of the products of that gene.84 The transformed S. aureus mutants exhibited
a different phenotype than that of TZNB, host, and vector control. When the transformed clones
were grown in broth media the cells were observed to settle to the bottom of the culture tubes but
were easily resuspended. One hypothesis is that the gene products were being over expressed in
the cells causing this observed difference in phenotype. Future experiments should be done to
determine if the gene products are actually being over expressed by sarA in pCM29, such as
qPCR.
To explore the significance of each strain’s resistance, growth inhibition was compared
between host, vector control, and TZNB. Sequencing of the gene within the pCM29 construct
confirmed the presence or absence of the in silico predicted SNP variants. Looking at the
likelihood scores reported, it is again not surprising that the DNA-directed RNA polymerase
alpha subunit and the thioredoxin-fold protein had confirmed mutations. The phosphoserine
phosphatase was predicted to be truncated by forty-three amino acids, but the mutation was not
confirmed and therefore the whole gene would have been transcribed in TZNB. However, due to
the primer design based on this predicted mutation, the protein was accidently truncated by
thirty-six amino acids. The EC50 of drug-resistant TZNB was determined to be two-fold greater
than the host, vector control and WT 13709, which can be confirmed as drug-resistant. All of the
transformed mutants’ EC50 values were determined to be less than that of the TZNB and closer to
the EC50 values for host and vector controls, which demonstrates that none of the predicted SNPs
variants confirm resistance to 31G12 when expressed in the RN4220/pCM29 system. Closer
examination of the dose-response curves shows that L11 methyltransferase and the thioredoxin-
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fold protein exhibit increased maximum growth at sub-inhibitory concentrations of 31G12. It is
possible that these mutations and over expression of these genes results in increased fitness at
sub-inhibitory concentrations of 31G12 but currently does not confirm that either of these
proteins is the target for 31G12 and the mode of action.
In summary, our whole-genome sequencing approach revealed multiple mutations in S.
aureus drug-resistant strains TZNB and TZNP. The results suggest that the use of the
bioinformatic system PATRIC was a good approach for determining genetic variation among
different strains. Although the mode of action for 31G12 has not been confirmed, the results
yielded six potential proteins; two of which are good candidates for further studies. Future
research should examine the levels of gene expression using the RN4220/pCM29 system and
plasmid stability studies of pCM29 to ensure that the plasmid is not being lost from the clones
during the drug inhibition studies. Another alternative for drug inhibition studies and conferring
resistance to 31G12 is use of a new system RN4220/pTet15. The significance of finding the
mode of action for 31G12 in S. aureus is for future studies involving crystallization of the target
protein for a target-based drug development approach for new antibiotics.
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CHAPTER V. CONCLUSIONS
Staphylococcus aureus is a Gram-positive bacterial pathogen responsible for nosocomial
and community-acquired infections. Its ability to quickly acquire antibiotic resistance has made
it practically resistant to all known antibiotics. Here, we have identified a novel triazole
antimicrobial 31G12 based on the natural product core of nonactin. We have demonstrated that
this novel antimicrobial is active against multiple Gram-positive bacteria as well as antibioticresistant MRSA and VRE. The synthesis and characterization of 31G12 indicated it exists as a
mixture of two rotamers and was used to select for S. aureus resistant mutants TZNB and TZNP
for target elucidation studies to determine the mode of action. It was also determined that 31G12
is a bacteriostatic antimicrobial against S. aureus with moderate mammalian cell toxicity.
We have currently revealed potential protein targets of 31G12 in S. aureus by a chemical
proteomic strategy that utilized 31G12 based photoaffinity-cross-linking probe JH-7-088. It was
established that probe JH-7-088 and biotin-azide tag JH-7-022 binds to a protein at
approximately 110 kDa when visualized via western blot. The probe was competitively
displaced with 31G12 and displayed a strong dose-response with increasing concentrations.
Preliminary results using azide-fluor 545 instead of the biotin-streptavidin tag also suggest that a
protein at ~110 kDa is being labeled via in-gel scans. This evidence suggest that the protein of
interest and potential target for antimicrobial 31G12 is a protein(s) with a molecular weight of
~110 kDa, but further experiments are needed to verify these results.
Using whole-genome sequencing and a bioinformatic approach to target elucidation of
31G12 revealed multiple mutations in S. aureus drug resistant-strains TZNB and TZNP. The
bioinformatic system PATRIC was a good approach for determining genetic variations among
the different strains and yielded six potential protein targets of 31G12. Two of these proteins,
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thioredoxin-fold protein and L11 methyltransferase, were determined to be good candidates
based on dose-response curves. Future studies could be done to verify if either of these proteins
contributes to resistance against 31G12 in S. aureus and therefore reveal the mode of action.
Although the mode of action for novel antimicrobial 31G12 has not been established we
are confident that we are close to finding it. More broadly, this work highlights the use of an
interdisciplinary approach to elucidate the target of a novel antimicrobial thereby providing a
rational framework for expanding efficacy. To expand this efficacy, future structure-based drugs
designed on the mode of action for antimicrobial 31G12 could be investigated to produce a more
potent antimicrobial against Gram-positive bacteria with lowered toxicity to mammalian cells.
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CHAPTER VI. SYNTHESIS EXPERIMENTALS
Synthesis of 31G12

Methyl Nonactate
Methyl nonactate was purified from a mixture of methyl nonactate and methyl homononactate
by column chromatography and eluted with EtOAc/Hexanes (10%-90%). 1H NMR (400 MHz,
CDCl3-d) δ ppm 1.06 (d, J=7.03 Hz, 3H), 1.13 (d, J=6.27 Hz, 3H), 1.49-1.69 (m, 4H), 1.88-1.99
(m, 2H), 2.42-2.53(m, 1H), 3.02 (s, 1H), 3.62 (s, 3H), 3.89-3.99 (m, 3H).

Methyl (S)-2-((2S,5R)-5-((R)-2-(tosyloxy)propyl)tetrahydrofuran-2-yl)propanoate85
Methyl nonactate 1 (1.015 g, 4.62 mmol) was dissolved in CHCl2 (10 mL). Pyridine (1.2 mL,
13.9 mmol) and pTsCl (1.375 g, 6.93 mmol) were added and reaction was stirred at room
temperate for 18 h. The reaction mixture was diluted with EtOAc, washed with aq. CuSO4 (3 x
10 mL), and aq. NH4Cl (10 mL) and then dried over anhyd. NaSO4. The solvent was removed
by evaporation in vacuo. The crude product was purified by column chromatography and eluted
with EtOAc/Hexanes (1:9) to yield 2 ( 0.725 g , 75%). 1H NMR (400 MHz, CDCl3-d) δ ppm
1.07 (d, J=7.03 Hz, 3H), 1.32 (d, J=6.27 Hz, 3H), 1.47-1.69 (m, 2H), 1.79-1.93 (m, 3H), 2.422.48 (m, 4H), 3.54-3.62 (m, 1H), 3.69 (s, 3H), 3.73-3.80 (m, 1H), 4.73-4.81 (m, 1H), 7.33 (d,
J=8.03 Hz, 2H), 7.78 (d, J=7.69 Hz, 2H).
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Methyl (S)-2-((2S,5R)-5-((S)-2-azidopropyl)tetrahydrofuran-2-yl)propanoate85
Sodium azide (2.6470 g, 40.7 mmol) was dissolved in DMSO (8.5 mL) and added to a solution
of 2 (0.7272 g, 3.24 mmol) in DMSO (15 mL). The mixture heated at reflux for 18 h. The
reaction mixture was diluted with H2O and extracted with EtOAc (2 x 15 mL). The organic
phase was washed with aq. NaHCO3 (2 x 10 mL), and brine (10 mL), and then dried over anhyd.
Na2SO4. The solved was removed by evaporation in vacuo to yield 3 (0.634 g, 92%). 1H NMR
(400 MHz, CDCl3-d) δ ppm 1.12 (d, J=7.03 Hz, 3H), 1.28 (d, J=6.53 Hz, 3H), 1.49-1.72 (m,
3H), 1.80-1.89 (m, 1H), 1.93-2.09 (m, 2H), 2.53 (dd, J=7.91, 7.15 Hz, 1H), 3.51-3.62 (m, 1H),
3.70 (s, 3H), 3.90-3.99 (m, 1H), 4.03 (d, J=8.03 Hz, 1H).

(S)-2-((2S,5R)-5-((S)-2-Azidopropyl)tetrahydrofuran-2-yl-propanoic acid85
Compound 3 (0.7272 g, 3.24 mmol) was dissolved in THF (14.5 mL) to which H2O (7.3 mL)
was added. LiOH (0.7858 g, 32.4 mmol) was added to the solution which was stirred at room
temperature for 18 h. The reaction was diluted with EtOAc and washed with aq. 1% (w/v)
NaOH ( 3 x 20 mL). The aqueous layers were combined and cooled to 0 °C and then acidified
with aq. 1 M HCl, and washed with EtOAc (2 x 10 mL). The combined organic phases were
washed brine (2 x 10 mL), dried over anhyd. Na2SO4. The solvent was removed by evaporation
in vacuo to yield 4 (0.558 g, 81%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.00 (d, J=7.03 Hz,
3H), 1.22 (d, J=6.53 Hz, 3H), 1.44-1.65 (m, 3H), 1.71 (dt, J=13.74, 7.06 Hz, 1H), 1.84-2.02 (m,
2H), 2.31-2.41 (m, 1H), 3.54-3.65 (m, 1H), 3.80-3.95 (m, 2H), 12.06 (br s, 1H).
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(S)-2-((2S,5R)-5-((S)-2-Azidopropyl)tetrahydrofuran-2-yl-propanoyl chloride
Compound 4 (0.266 g, 1.17 mmol) was dissolved in CHCl2 (6 mL) and cooled to 0 °C, after
which oxalyl chloride (0.41 mL, 4.7 mmol) and two drops of DMF were added. The mixture
was stirred for 18 h. The reaction mixture was concentrated by evaporation in vacuo yielding 5
(.288 g, 100%).

2-(3,4-Dichlorophenyl)-N-(thiazol-5-ylmethyl)ethanamine86
Thiazole-5-carbaldehyde 7 (0.55 mL, 6.35 mmol) and NaBH4 (0.3844 g, 8.46 mmol) were added
to MeOH (6mL), and then 3,4-dichlorophenethylamine 6 (0.6 mL, 4.23 mmol) was added and
stirred for 1 h at room temperature. The reaction was diluted with water and acidified with aq. 1
M HCl to pH 1 and washed with CH2Cl2 (3 x 20 ml). The aqueous phases were adjusted to pH
10 with 10% NaOH and extracted with CH2Cl2 (3 x 15 mL), and washed with brine, and then
dried over anhyd. Na2SO4. The solution was concentrated in vacuo yielding 8 (0.8101 g,
70.5%). 1H NMR (400 MHz, DMSO-d6) δ ppm 2.34 (br s, 1H), 2.67-2.85 (m, 5H), 3.93 (s, 2H),
7.20 (dd, J=8.19, 2.08 Hz, 1H), 7.46-7.56 (m, 2H), 7.73 (s, 1H), 8.95 (s, 1H).

13

C NMR (CDCl3-

d, 100 MHz) δ 152.8, 140.8, 140.0, 138.4, 132.3, 130.6, 130.3, 130.2, 128.1, 49.6, 45.4, and 35.4
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tert-Butyl 4-hydroxypiperidine-1-carboxylate87
4-hydroxypiperdine 9 (2.0095 g, 19.7 mmol) and trimethylamine (TEA) (6.3 mL, 39.5 mmol)
were dissolved in THF (18 mL) and Boc2O (5.5 mL, 39.5 mmol) was added then stirred at room
temperature for 18 h. THF was removed by evaporation in vacuo and the product was dissolved
in EtOAc (10 mL) and washed with brine (2 x 10 mL), and dried over anhyd. Na2SO4 and then
solvent removed by evaporation in vacuo. The crude product was purified by column
chromatography and eluted in EtOAc/Hexanes (10-75%) to yield 10 (2.371 g, 59%). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.14-1.31 (m, 2H), 1.33-1.44 (s, 9H), 1.59-1.72 (m, 2H), 2.94 (br s,
2H), 3.55-3.85 (m, 3H), 4.69 (d, J=4.27 Hz, 1H).

tert-Butyl 4-oxopiperidine-1-carboxylate88
Oxalyl chloride (1.872 g, 15.2 mmol) was dissolved in CH2Cl2 (15 mL) and cooled to -78 °C.
DMSO (2.1 mL, 29.5 mmol) in CH2Cl2 (6 mL) was added to the reaction mixture and stirred for
15 min. Compound 10 (2.3394 g, 11.8 mmol) was dissolved in CH2Cl2 (6 mL) and added to the
reaction mixture and stirred for 1 h before the addition of Et3N (4.9 mL, 35.1 mmol) and then
stirred for an additional 20 minutes. The reaction was allowed to come to room temperature over
18 h. The reaction was washed with H2O (2 x 20 mL) and dried over anhyd. Na2SO4 and then
the solvent was removed by evaporation in vacuo. The crude product was purified by column
69

chromatography and eluted in EtOAc/Hexanes (1:4) to yield 11 (1.357 g, 73%). 1H NMR (400
MHz, CDCl3-d) δ ppm 1.42 (s, 9H), 2.37 (t, 4H), 3.65 (t, 4H).

tert-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate89
Magnesium turnings (0.43 g, 16.6 mmol), THF (10 mL) and a crystal of iodine were added to a
dry 3 neck flask equipped with an addition funnel and reflux condenser. 1-Bromo-4chlorobenzene 12 (3.178 g, 16.6 mmol) in THF (10 mL) was added to the addition funnel and
slowly added to the reaction mixture. The solution was stirred and heated at heated at reflux for
an hour before being cooled to 0 °C in an ice bath. A solution of 11 (0.661 g, 3.3 mmol) in THF
(10 mL) was added dropwise via the addition funnel to the reaction solution and heated at reflux
for 1 h. After reaching room temperate, the reaction was quenched with NH4Cl and extracted
with EtOAc (3 x 20 mL), and then dried over anhyd. Na2SO4 and the solvent was removed by
evaporation in vacuo. The crude product was purified by column chromatography and eluted
with EtOAc/Hexanes (5-30%) to yield 13 (0.187 g, 27%). 1H NMR (400 MHz, CDCl3-d) δ ppm
1.26 (t, J=7.09 Hz, 1H), 1.48 (s, 9H), 1.96 (td, J=13.20, 4.89 Hz, 2H), 2.05 (s, 1H), 3.22 (td,
J=13.02, 2.81 Hz, 2H), 3.99-4.09 (m, 2H), 4.12 (q, J=7.09 Hz, 1H), 7.30-7.37 (m, 2H), 7.39-7.45
(m, 2H).
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4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridine90
Compound 13 (3.627 g, 11.7 mmol) was dissolved in CH2Cl2 (55 mL) and triethylsilane (9.2 mL,
58.5 mmol) was added and then cooled to 0 °C. Trifluoroactetic acid (TFA) (21.5 mL, 280.8
mmol) was slowly added to the mixture and stirred for 24 h. 1 M NaOH (25 mL) was added to
the reaction mixture and stirred for 20 min before being washed with CH2Cl2 (2 x 30 mL). The
organic phases were combined and washed with aq. Brine (2 x 10 mL) and then dried over
anhyd. Na2SO4. The solvent was removed by evaporation in vacuo to yield 14 (1.484, 65%). 1H
NMR (400 MHz, CD3OD-d4) δ ppm 2.68-2.76 (m, 2H), 3.56 (s, 3H), 3.72 (br d, J=2.93 Hz, 2H),
6.43 (br s, 1H), 7.55 (d, J=8.56 Hz, 2H), 7.65 (d, J=8.56 Hz, 2H).

4-(4-Chlorophenyl)piperidine91
Compound 14 (2.26 g, 11.67 mmol) was dissolved in MeOH (58 mL) and Pd/C (0.6224 g, 5.83
mmol) was added. The solution was stirred vigorously under a H2 pressurized balloon for 6 h at
room temperature. The reaction was filtered through a MeOH celite slurry and then the solvent
was removed by evaporation in vacuo. The crude product was dissolved in EtOAc and washed
with 1 M NaOH (2 x 25 mL), NaOH/brine (1:1, 2 x 25 mL), and then dried over anhyd. Na2SO4.
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The solvent was removed by evaporation in vacuo to yield 15 (1.972, 86%).

4-(4-chlorophenyl)-1-(prop-2-yn-1-yl)piperidine92
Compound 15 (0.7624 g, 3.9 mmol) was dissolved in THF (4 mL) and added to a solution of
propargyl bromide (0.46 mL, 4.09 mL) in THF (1 mL). The reaction was wrapped in tin foil and
stirred for 7 min before the addition of K2CO3 (1.0920 g, 7.79 mmol) and reacted at room
temperature for 18 hr. The reaction mixture was diluted with EtOAc and washed with aq. 1 M
NaOH (2 x 5 mL), aq. 1 M NaOH/brine (1:1, 10 mL), and then dried over anhyd. Na2SO4. The
solvent was removed by evaporation in vacuo. The crude product was purified by column
chromatography and eluted with EtOAc/Hexanes (1:4) to yield 16 (0.469, 51%).

(S)-2-((2S,5R)-5-((S)-2-Azidopropyl)tetrahydrofuran-2-yl)-N-(3,4-dichlorophenethyl)-N(thiazol-5-ylmethyl)propenamide
Compound 8 (0.396g, 1.44 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 °C, after
which Et3N (0.22 mL, 1.51 mmol) was added to the solution. Compound 5 (0.439g, 1.38 mmol)
was dissolved in CH2Cl2 (2.5 mL) and slowly added to the reaction mixture and then stirred for
18 h. The reaction was diluted with aq. Na2CO3 and then stirred for five min, before extraction
with EtOAc (10 mL) and washed with H2O (1 x 10 mL) to yield crude 17 (0.387 g, 48%).
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2-(5-(2-(4-((4-(4-Chlorophenyl)piperidin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)tetrahydrofuran-2-yl)-N-(3,4-dichlorophenethyl)-N-(thiazol-5ylmethyl)propanamide93

Crude 17 (0.387, 0.78 mmol) and 16 (0.197 g, 0.79 mmol) were dissolved in t-BuOH (1.4 mL)
and then H2O (1.4 mL) was added. CuSO4·5H2O (0.00214 g, 0.078 mmol) was added
immediately followed by sodium ascorbate (0.0323 g, 0.16 mmol) and then stirred at room
temperature 18 h. The reaction was diluted with EtOAc and washed with H2O (2 x 5 mL), then
aq. brine (10 mL) and the solvent was removed by evaporation in vacuo. The crude product was
purified by column chromatography and eluted with EtOAc/Hexanes (1:4) (0.052 g, 21%). 1H
NMR (400 MHz, CDCl3-d) δ ppm 0.91-1.15 (m, 3H), 1.42-1.61 (m, 5H), 1.68-2.23 (m, 10H),
2.43-2.79 (m, 2H), 2.80-2.92 (m, 2H), 3.01-3.11 (m, 2H), 3.44-3.62 (m, 1H), 3.62-3.86 (m, 4H),
3.90-4.06 (m, 1H), 4.53-4.94 (m, 3H), 6.97-7.10 (m, 1H), 7.11-7.19 (br d, J=7.95 Hz, 2H), 7.227.53 (m, 5H), 7.72-7.78 (m, 1H), 8.71-8.79 (m, 1H).

13

C NMR (CHLOROFORM-d, 100 MHz) δ

175.2, 175.0, 154.1, 153.5, 144.7, 144.6, 142.2, 141.4, 139.2, 138.3, 134.6, 132.7, 131.7, 131.0,
130.8, 130.8, 130.7, 130.4, 128.5, 128.3, 128.2, 128.2, 120.0, 119.9, 82.0, 81.9, 77.2, 75.5, 75.3,
54.5, 54.4, 54.1, 53.8, 53.7, 48.4, 48.1, 44.9, 43.9, 43.5, 42.3, 42.1, 41.8, 41.7, 34.8, 33.3, 33.0,
30.9, 29.1, 20.6, 20.5, 14.7, and 14.2.
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Synthesis of Photoaffinity Probe JH-7-088

Methyl (S)-2-((2S,5R)-5-((R)-2-(tosyloxy)propyl)tetrahydrofuran-2-yl)propanoate94
Methyl nonactate (1) (5.4 g, 25 mmol) was dissolved in CH2Cl2 (37 mL). Et3N (7.6 mL, 54.9
mmol) was added to the reaction mixture and cooled to 0 C, after which p-TsCl (10.1 g, 52.4
mmol) and a catalytic amount of DMAP (0.003 g, 0.025 mmol) were added. The solution was
stirred for 22 h and allowed to come to room temperature. The reaction mixture was diluted with
CH2Cl2 (10 mL) and washed with aq. Brine (2 x 20 mL). The organic layer was dried over
anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo. A yellow oil was
obtained and purified with column chromatography and eluted with EtOAc/Hexanes (5%-60%)
yielding 2 (6.82 g, 74%).

Methyl (S)-2-((2S,5R)-5-((S)-2-azidopropyl)tetrahydrofuran-2-yl)propanoate95
Compound 2 (6.8 g, 18.4 mmol) was dissolved in DMF (175 mL) and NaN3 (6.4, 92.0 mmol)
was added to the solution. The reaction was heated at reflux for three h before cooling to room
temperature. The reaction mixture was extracted with EtOAc and quenched with H2O. The
organic layer was collected, and the solvent was removed by evaporation in vacuo to yield 3 a
yellow oil (4.40 g, 99%).
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(S)-2-((2S,5R)-5-((S)-2-Azidopropyl)tetrahydrofuran-2-yl)propanoic acid85
Crude 4 (2.2 g, 9.1 mmol) was diluted in Et2N (11 mL) and MeOH (11 mL) to which H2O (3.8
mL) was added along with LiOH·H2O (2.1 g, 47.9 mmol) and stirred for 24 h. The reaction
mixtures was extracted with EtOAc and acidified with aq. 2 M HCl. The organic layer was
washed with HCl (aq. 0.5 M, 20 mL) and acidified brine (20 mL) before collected and then dried
over anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo to yield 4 a yellow oil
(1.97 g, 95%).

4-(4-Chlorophenyl)-1-(prop-2-yn-1-yl)piperidine 92
4-(4-Chlorophenyl)piperdine 5 (0.4 g, 2.0 mmol) was dissolved in THF (20 mL) to which
propargyl bromide (80% wt. in toluene, 0.30 mL, 2.6 mmol) was then added. The mixture was
wrapped in tin foil and stirred for seven min before the addition of potassium carbonate (0.6 g,
4.1 mmol) and then stirred at room temperature for 2.5 h. The reaction mixture was extracted
with EtOAc (20 mL) and washed with aq. 0.5 M NaOH (2 x 10 mL), basified brine (2 x 10 mL),
dried over anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo to yield 6 an
orange solid (0.5 g, 18%).
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(S)-2-((2S,5R)-5-((S)-2-(4-((4-(4-Chlorophenyl)piperidin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)tetrahydrofuran-2-yl)propanoic acid6
Compound 3 (0.2 g, 0.9 mmol) was dissolved in t-BuOH (0.7 mL). Compound 6 (0.2 g, 0.9
mmol) was dissolved in t-BuOH (1 mL) and both 3 and 6 were added to a round bottom flask.
To the mixture was added H2O (1.7 mL), CuSO4·5H2O(0.03 g, 0.09 mmol) and soduim ascorbate
(0.09 g, 0.4 mmol) and the mixture was heated at 40 °C for 23 h. The reaction mixture was
diluted with EtOAc (3 mL), then washed with brine (2 x 0 mL) and organic layer was dried over
anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo to yield 7 an orange brown
solid. Crude product was purified by reserve phase LC with MeOH/H2O, to yield a white solid
(0.7 g, 18 %).

2-(4-Bromophenyl)-1,3-dioxolane97
4-Bromobenaldehyde (24.9 g, 135.1 mmol) was dissolved in toluene (155 mL) to which ethylene
glycol (11.5 mL, 202.7 mmol) and p-TsOH (0.1747, 0.5 mmol) were added to the reaction
mixture and heated at reflux for 30 h. The reaction was quenched with saturated aq. NaHCO3,
washed with brine (2 x 50 mL), then dried over anhyd. NaSO4 and the solvent was removed by
evaporation in vacuo to yield 8, a clear oil (30.60 g, 99%). 1H NMR (400 MHz, CDCl3-d) δ ppm
4.00-4.16 (m, 4H), 5.78 (s, 1H), 7.36 (d, J=8.31 Hz, 2H), 7.52 (d, J=8.44 Hz, 2H).
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1-(4-(1,3-Dioxolan-2-yl)phenyl)-2,2,2-trifluoroethanone97
Compound 8 (4.4 g, 19.3 mmol) was dissolved in THF (90 mL) and cooled to -78 C before nBuLi (2.5 M in hexanes, 9.3 mL, 23.1 mmol) was added and then stirred for 1.5 h. Ethyl
trifluoroacetate (3 mL, 25.1 mmol) in THF (5 mL) was added to the mixture and then stirred for
18 h at room temperate. The reaction mixture was quenched with aq. NH4Cl and diluted with
EtOAc (50 mL), washed with water (2 x 25 mL) and brine (2 x 25 mL). The organic layer was
dried over anhyd. NaSO4 and the solvent was removed by evaporation in vacuo to yield 9, a
yellow oil (4.7 g, 78%). Compound 9 was used in subsequent step without further purification.
1

H NMR (400 MHz, DMSO-d6) δ ppm 3.93-4.10 (m, 4H), 5.88 (s, 1H), 7.72 (d, J=8.31 Hz, 2H),

8.08 (d, J=7.95 Hz, 2H)

1-(4-(1,3-Dioxolan-2-yl)phenyl)-2,2,2-trifluoroethanone oxime98
Compound 9 (4.7 g, 19.3 mmol) was dissolved in pyridine (39 mL), to which hydroxylamine
(4.7 g, 57.8 mmol) was added and heated at reflux for two h. The solvent was removed by
evaporation in vacuo to yield 10, a crude yellow oil (6.39 g).
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1-(4-(1,3-Dioxolan-2-yl)phenyl)-2,2,2-trifluoroethanone O-tosyl oxime94
Compound 10 (4.9 g, 18.9 mmol) was dissolved in CH2Cl2 (35 mL) and Et3N (8 mL, 56.7 mmol)
was added to the mixture before being cooled to 0 C. pTsCl (7.4 g, 37.8 mmol) and a catalytic
amount of DMAP (0.002 g, 0.0025 mmol) were added to the mixture and after 1.5 h the reaction
mixture was concentration by evaporation in vacuo to near dryness and diluted with EtOAc and
washed with H2O (25 mL), aq. brine (25 mL) and the organic layer was dried over anhyd.
Na2SO4 and then concentrated again by evaporation in vacuo. The crude reaction was purified
by column chromatography and eluted with EtOAc/Hexanes (2.5%-10%) to yield 11, a yellow
solid (3.7 g, 47%). 1H NMR (400 MHz, CDCl3-d) δ ppm 2.45-2.56 (m, 3H), 4.01-4.20 (m, 4H),
5.79-5.90 (m, 1H), 7.30-8.03 (m, 8H)

3-(4-(1,3-dioxolan-2-yl)phenyl)-3-(trifluoromethyl)diaziridine99
Compound 11 (2.7 g, 8.8 mmol) was dissolved in Et2O (10 mL) and cooled to -78 C. Liquid
ammonia (30 mL) was added to the flask and then stirred for 30 m at -78 C, 1.5 h at 0 C and
cooled back to -78 C. The flask was then opened to allow the ammonia to slowly evaporate.
The mixture was diluted with Et2O (10 mL) and H2O (10 mL), then washed with H2O (10 mL),
aq. brine (10 mL) and the organic layer was dried over anhyd. NaSO4 and then the solvent was
removed by evaporation in vacuo to yield 12, a yellow orange powder (1.7 g, 74% yield). 1H
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NMR (500 MHz, CDCl3-d) δ ppm 2.19-2.25 (d, J=8.80 Hz, 1H), 2.78-2.84 (d, J=8.31 Hz, 1H),
4.03-4.16 (m, 4H), 5.85 (s, 1H), 7.51-7.60 (d, J=8.31 Hz, 2H), 7.62-7.73 (d, J=8.31 Hz, 2H).

3-(4-(1,3-Dioxolan-2-yl)phenyl)-3-(trifluoromethyl)-3H-diazirine99
Compound 12 (0.8 g, 2.9 mmol) was diluted in CH2Cl2 (8 mL) with Et3N (0.9 mL, 5.8 mmol),
wrapped in tin foil and cooled to 0 C. Iodine (0.9 g, 3.2 mol) was added to the reaction and then
stirred for ten min before being brought to room temperate and allowed to react for 24 h. The
reaction was quenched with aq. NaHCO3 and extracted into CH2Cl2. The organic layer was
washed with CH2Cl2 (10 mL), aq. 1 M NaOH (10 mL), H2O (10 mL) and brine (10 mL) before
being dried over anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo to yield a
yellow powder. The crude product was purified with column chromatography and eluted with
EtOAc/Hexanes (5%-20%) to yield 13 (0.778 g). 1H NMR (500 MHz, CDCl3-d) δ ppm 4.024.14 (m, 4H), 5.83 (s, 1H), 7.19-7.28 (d, J=7.83 Hz, 2H), 7.53 (d, J=8.31 Hz, 2H).

13

C NMR

(CDCl3-d, 100 MHz) δ 139.7, 129.9, 126.9, 126.5, 123.4, 120.7, 102.8, and 65.3

4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzaldehyde100
Compound 14 (0.8 g, 3.0 mmol) was dissolved in acetone (24 mL) and H2O (12 mL) and then
cooled to 0 C, to which aq. sulfuric acid (0.5 M, 30 mL) was added slowly, brought to room
temperature and stirred for 18 h in the dark. The reaction was quenched with saturated NaHCO3
and extracted with CH2Cl2. The organic layer was washed with brine (20 mL) and dried over
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anhyd. Na2SO4. The solvent was removed by evaporation in vacuo to yield 14, a yellow oil
(0.36 g, 80%). 1H NMR (500 MHz, CDCl3-d) δ ppm 7.34-7.38 (d, J=8.31 Hz, 2H), 7.90-7.95 (d,
J=8.31 Hz, 2H), 10.05 (s, 1H).

N-(4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzyl)prop-2-yn-1-amine 101
Compound 14 (0.2 g, 0.9 mmol) was dissolved in CH2Cl2 (0.95 mL) and acetonitrile (0.95 mL).
Propargylamine (0.18 g, 2.8 mmol) was added to the mixture and cooled to 0 C and then stirred
for 15 min before NaB(OAc)3 (0.6 g, 2.8 mmol) was added. The mixture was stirred for 24 h in
the dark before being diluted with EtOAc (5 mL) and quenched with H2O (5 mL). The organic
layer was washed with H2O ( 2 x 5 mL), saturated NaHCO3 (2 x 5 mL), brine (5 mL) and then
dried over anhyd. Na2SO4 and then concentrated by evaporation in vacuo. The crude product
was purified with column chromatography and eluted with EtOAc/Hexanes (5%-25%) to yield
15, a yellow oil (0.12 g, 51%). 1H NMR (500 MHz, CDCl3-d) δ ppm 2.27 (t, J=2.45 Hz, 1H),
3.41 (d, J=2.45 Hz, 2H), 3.91 (s, 2H), 7.17 (d, J=8.31 Hz, 2H), 7.36-7.44 (d, J=8.80 Hz, 2H).
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(S)-2-((2S,5R)-5-((S)-2-(4-((4-(4-Chlorophenyl)piperidin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)tetrahydrofuran-2-yl)-N-(prop-2-yn-1-yl)-N-(4-(3-(trifluoromethyl)-3H-diazirin3-yl)benzyl)propanamide 102
Compound 7 (0.07 g, 0.12 mmol) was dissolved in DMF (0.4 mL) and cooled to 0 C, after
which HOBt hydrate (0.033 g, 0.18 mmol) and EDC (0.04 g, 0.18 mmol) were added.
Compound 15 (0.04 g, 0.14 mmol) was dissolved in DMF (0.3 mL) and added to the reaction
and then stirred for 18 h in the dark. The reaction was diluted with EtOAc (10 mL) and
quenched with H2O (2 mL). The organic layer was washed with H2O (2 x 10 mL), brine (10
mL), and then dried over anhyd. Na2SO4 and the solvent was removed by evaporation in vacuo.
The crude product was purified by column chromatography and eluted with EtOAc/Hexanes
(25%-100%) to yield JH-7-088, white crystals (0.23 g, 22 %). 1H NMR (400 MHz, CDCl3-d) δ
ppm 0.77-1.21 (m, 5H), 1.22-1.32 (br s, 2H), 1.41-1.65 (m, 5H), 1.74-1.86 (br s, 3H), 1.88-2.35
(m, 6H), 2.43-2.56 (br s, 1H), 2.60-2.97 (m, 1H), 3.04-3.17 (m, 2H), 3.70-3.87 (m, 3H), 3.964.07 (m, 1H), 4.18-4.33 (m, 1H), 4.35-4.43 (br d, J=16.26 Hz, 1H), 4.62-5.15 (m, 2H), 7.08-7.22
(m, 4H), 7.23-7.29 (m, 2H), 7.29-7.37 (m, 2H).

13

C NMR (CDCl3-d, 100 MHz) δ 175.2, 144.5,

139.2, 138.7, 131.8, 128.5, 128.5, 128.5, 128.2, 128.1, 127.1, 126.9, 126.6, 123.5, 120.7, 120.2,
82.3, 81.9, 78.8, 78.7, 75.4, 75.4, 72.9, 72.2, 54.6, 54.4, 54.0, 53.9, 53.6, 49.6, 48.4, 43.8, 43.6,
41.9, 41.7, 37.0, 34.7, 33.1, 31.0, 30.9, 29.7, 29.2, 29.0, 28.9, 28.5, 28.1, 27.7, 20.7, 20.2, 14.5,
and 14.4
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Synthesis of Tag

6-Hydroxyhexyl tert-butylcarbamate 98
6-Amino-1-hexanol 1 (2 g, 17 mmol) was dissolved in CH2Cl2 (30 mL). Boc2O anhydride (3.9
g, 17 mmol) was dissolved in CH2Cl2 (20 mL) and Et2N (2.6 mL, 18.9 mmol) were then added to
the reaction mixture and reacted for 3 h. The mixture was concentration in vacuo to yield 2 a
brown oil (3.7 g, 99%).

6-((tert-Butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate 94
Crude 2 (3.7 g, 17.1 mmol) was dissolved in CH2Cl2 (25 mL), and Et3N (3.1 mL, 25.6 mmol) at
0 C, then p-TsCl (4 g, 20.5 mmol) and a crystal DMAP were added to the solution. After
stirring for 18 h at room temperate, the reaction was diluted with CH2Cl2 and washed by brine
(25 mL), and then extracted with CH2Cl2 (25 mL) and washed once more with brine (25 mL)
before the organic layer was dried over anhyd. Na2SO4 and the solvent was removed by
evaporation in vacuo to yield 3 a brown oil (6.41 g, 100%).
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tert-Butyl (6-azidohexyl)carbamate 95
Compound 3 (6.3 g, 17.1 mmol) was dissolved in DMSO (150 mL), then NaN3 (5.9 g, 85.3
mmol) was added and then stirred for 3 h. The reaction mixture was diluted with EtOAc,
washed with water (3 x 50 mL), brine (50 mL), and then dried over anhyd. NaSO4. The solvent
was removed by evaporation in vacuo. The crude product was purified by column
chromatography and eluted with EtOAc/Hexanes (10%-50%) to yield 4 a clear oil (0.77 g, 19%).
1

H NMR (400 MHz, CDCl3-d) δ ppm 1.31-1.54 (m, 15H), 1.56-1.65 (quin, J=7.00 Hz, 2H),

3.07-3.17 (br t, J=6.05 Hz, 2H), 3.23-3.31 (t, J=6.91 Hz, 2H), 4.39-4.66 (br s, 1H).

6-Azidohexan-1-amine 103
Compound 4 (0.76 g, 3.1 mmol) was dissolved in CH2Cl2 and cooled to 0 C, and then TFA (1.5
mL) was added and brought to room temperate and finally stirred for an additional hour. The
reaction mixture was diluted with CH2Cl2 and then quench with aq. 1 M NaOH to yield 5 a light
brown oil (0.4 g, 89%). 1H NMR (400 MHz, CDCl3-d) δ ppm 1.20-1.52 (m, 8H), 1.54-1.67
(quin, J=6.85 Hz, 2H), 2.65-2.75 (t, J=6.85 Hz, 2H), 3.23-3.31 (t, J=6.85 Hz, 2H).
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N-(6-Azidohexyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl)pentanamide 104

Biotin 6 (0.3 g, 1.22 mmol) was dissolved in DMF (2mL), then HBOt·H2O (0.24 g, 1.22 mmol)
and EDC (0.29 g, 1.47 mmol) were added and stirred for 5 min before the addition of 5 (0.23 g,
1.6 mmol) and stirred for an additional 24 h. The reaction was diluted with EtOAc and H2O and
washed with H2O (10 mL), brine (10 mL) and then dried over anhyd. NaSO4. The solvent was
removed by evaporation in vacuo and the crude product was purified with column
chromatography and eluted with EtOAc/Hexanes (25%-100%) to yield JH-7-022 a white solid
(.025 g, 5.5%.). 1H NMR (400 MHz, CDCl3-d) δ ppm 1.28-1.86 (m, 15H), 2.18-2.37 (t, J=7.27
Hz, 2H), 2.74-2.83 (d, J=12.84 Hz, 1H), 2.88-2.97 (dd, J=4.65, 12.84 Hz, 1H), 3.12-3.35 (m,
5H), 4.24-4.42 (m, 1H), 4.50-4.64 (m, 1H), 5.48-5.92 (br s, 1H), 6.34-6.73 (br s, 1H).

13

C NMR

(CDCl3-d, 100 MHz) δ 173.6, 163.9, 61.9, 60.4, 55.5, 51.3, 40.5, 39.6, 35.7, 29.4, 28.7, 28.0,
28.0, 26.5, 26.4, and 25.7
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Appendix A: Supplementary Information

Figure 1: Observed cooling of 31G12 variable temperature 1H NMR in DMSO-d6.
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Figure 2: Multiple sequence alignment using CLUSTAL O (1.2.4) of S.aureus 13709 WT and
drug -resistant strains TNZB and TZNP for all transformed mutants with indicated amino acid
changes.
CLUSTAL O(1.2.4) multiple sequence alignment
Ribosomal Protein L11 Methyltransferase
WT
MNWTELSIIINHEAVELATNILENHGSNGVVIEDSDDLINQPEDKYGEIYALKKEDYPDK 60
TZNB MNWTELSIIINHEAVELATNILENHGSNGVVIEDSDDLINQPEDKYGEIYALKKEDYPDK 60
TZNP MNWTELSIIINHEAVELATNILENHGSNGVVIEDSYDLINQPEDKYGEIYALKKEDYPDK 60
*********************************** ************************
WT
GVRLKAYFNEMTYDDKLRQRIKDELLNLDELDQQNVQFSEQIIAETDWENEWKNYFHPFR 120
TZNB GVRLKAYFNEMTYDDKLRQRIKDELLNLDELDQQNVQFSEQIIAETDWENEWKNYFHPFR 120
TZNP GVRLKAYFNELTYDDKLRQRIKDELLNLDELDQHNVQFSEQIIAETDWENEWKNYFHPFR 120
**********:**********************:**************************
WT
ASKKFTIVPSWETYAKEADEELCIELDPGMAFGTGDHPTTSMCLKAIETYVLPQHSVIDV 180
TZNB ASKKFTIVPSWETYAKEADEELCIELDPGMAFGTGDHPTTSMCLKAIETYVLPQHSVIDV 180
TZNP ASKKFTIVPSWETYAKEADEELCIELDPGMAFGTGDHPTTSMCLKAIETYVLPQHSVIDV 180
************************************************************
WT
GTGSGILSIASHLIGVKRIKALDIDEMAVSVAKENFRRNHCETLIEAVPGNLLKDETEKF 240
TZNB GTGSGILSIASHLIGVKRIKALDIDEMAVSVAKENFRRNHCETLIEAVPGNLLKDETEKF 240
TZNP GTGSGILSIASYLIGVKRIKALDIDEMAVSVAKENFRRNHCETLIEAVPGNLLKDETEKF 240
***********:************************************************
WT
DIVIANILAHIIDEMIEDAYNTLNEGGYFITSGIIKEKYEGIQSHMERVGFKIISEQHDN 300
TZNB DIVIANILAHIIDEMIEDAYNTLNEGGYFITSGIIKEKYEGIQSHMERVGFKIISEQHDN 300
TZNP DIVIANILAHIIDEMIDDAYNTLNEGGYFITSGIIKEKYEGIQSHMERVGFKIISEQHDN 300
****************:*******************************************
WT
GWVCLVGQKVSE 312
TZNB GWVCLVGQKVSE 312
TZNP GWVCLVGQKVSE 312
************

TZNB – no mutations
TZNP – D36Y, M71L, Q94H, H193Y, E257D
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CLUSTAL O(1.2.4) multiple sequence alignment
Transcriptional regulator, LysR family
WT
MNLDWYYTFVILAKTLNYRLASEEINLTIPSIHKQIKNLEQHLNVKLFETYKNQIILTED 60
TZNB MNLDWYYTFVILAKTLNYRLASEEINLTIPSIHKQIKNLEQHLNVKLFETYKNQIILTED 60
TZNP MNLDWYYTFVILAKTLNYRLASEEINLTIPSIHKQIKNLEQHLNVKLFETYKNQIILTED 60
************************************************************
WT
GHTFLPIAQSFIEQYESGIKHIQLKKTMFQSKLNVVVSSYIATFIMPKFLKSFFNEHPFI 120
TZNB GHTFLPIAQSFIEQYESGIKHIQLKKTMFQSKLNVVVSSYIATFIMPKFLKSFFNEHPFI 120
TZNP GHTFLPIAQSFIEQYESGIKHIQLKKTMFQSKLNVVVSSYIATFIMPKFLKSFFNEHPFI 120
************************************************************
WT
DVSLHVKNENIEKDINNHTYDIGISRNQPKLREVHSEKVCEGKIVLIAPNKENNHLLTEA 180
TZNB DVSLHVKNENIEKDINNHTYDIGISRNQPKLREVHSEKVCEGKIVLIAPNKENNHLLTEA 180
TZNP DVSLHVKNENIEKDINNHTYDIGISRNQPKLREVHSEKVCEGKIVLIAPNKENNHLLTEA 180
************************************************************
WT
PLFEKYKIISDNHPEYWSSLKNNILNIYEKAQFLSINDVHTSIKLIEMNQGISFLPIYIT 240
TZNB PLFEKYKIISDNHPEYWSSLKNNILNIYEKAQFLSINDVHTSIKLIEMNQGISFLPIYIT 240
TZNP SLFEKYKIISDNHPEYWSSLKNNILNIYEKAQFLSINDVHTSIKLIEMNQGISFLPIYIT 240
***********************************************************
WT
TNSDYNISVINTKILQAPISFTYIYSKKESPEILAFIKSFKKYIANEQL 289
TZNB TNSDYNISVINTKILQAPISFTYIYSKKESPEILAFIKSFKKYIANEQL 289
TZNP KNSNYNISVINTKILQAPISFTYIYSKKENPEILAFIKSFKKYIANEQL 289
.**:*************************.*******************

TZNB – none
TZNP – P181S, T241K, D244N, S270N
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Transcriptional regulator, LysR family
CLUSTAL O(1.2.4) multiple sequence alignment
WT
MDSLKVLTEVVKTQSFTKAAENLYTSQPSISRDIKRLELEYDVKIFEFRHSKMSLTSDGE 60
TZNB MDSLKVLTEVVKTQSFTKAAENLYTSQPSISRDIKRLELEYDVKIFEFRHSKMSLTSDGE 60
************************************************************
WT
KLFQYALQRERLEQNLRHDLKMQPDIISGDLTIGSSYTYGEYRLSQHLADLAKNYPELYI 120
TZNB KLFQYALQRERLEQNLRHDLKMQPDIISGDLTIGSSYTYGEYRLSQHLADLAKNYPELYI 120
************************************************************
WT
HVYLNNSDTVLQHIKNNTIDLGIIEKEVQSNIIHSRRIAQDEIVLIRKKSSSSNKSICFI 180
TZNB HVYLNNSDTVLQHIKNNTIDLGIIEKEVQSNIIHSRRIAQDEIVLIRKKSSSSNKSICFI 180
************************************************************
WT
RERGSGTRVYQENALSQMTSSSYLVEINNTNLIKNMVHADKGFSIVSKSTLTPYDLEKLE 240
TZNB RERGSGTRVYQENALSQMTSSSYLVEINNTNLIKNMVHADKGFSIVSKSTLTPYDLEKLE 240
************************************************************
WT
VTNLDIKRYFYLVIHKDKYIDTKLNEVIKNLIS 273
TZNB VTNLDIKRYFYLVIHKDKYIDTKLNEVIKNLIS 273
*********************************

TZNB – no mutations
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Lead, cadmium, zinc and mercury transporting ATPase (1)
WT
MANTKKTTLDITGMTCAACSNRIEKKLNKLDDVNAQVNLTTEKATVEYNPDQHDVQEFIN 60
TZNB MANTKKTTLDITGMTCAACSNRIEKKLNKLDDVNAQVNLTTEKATVEYNPDQHDVQEFIN 60
TZNP MANTKKTTLDITGMTCAACSNRIEKKLNKLDDVNAQVNLTTEKATVEYNPDQHDVQEFIN 60
************************************************************
WT
TIQHLGYGVAVETVELDITGMTCAACSSRIEKVLNKMDGVQNATVNLTTEQAKVDYYPEE 120
TZNB TIQHLGYGVAVETVELDITGMTCAACSSRIEKVLNKMDGVQNATVNLTTEQAKVDYYPEE 120
TZNP TIQHLGYGVAVETVELDITGMTCAACSSRIEKVLNKMDGVQNATVNLTTEQAKVDYYPEE 120
************************************************************
WT
TDADKLVTRIQKLGYDASIKDNNKDQTSRKAEALQHKLIKLIISAVLSLPLLMLMFVHLF 180
TZNB TDADKLVTRIQKLGYDASIKDNNKDQTSRKAEALQHKLIKLIISAVLSLPLLMLMFVHLF 180
TZNP TDADKLVTRIQKLGYDASIKDNNRDQTSRKAEALQHKLIKLIISAVLSLPLLMLMFVHLF 180
***********************:************************************
WT
NMHIPALFTNPWFQFILATPVQFIIGWQFYVGAYKNLRNGGANMDVLVAVGTSAAYFYSI 240
TZNB NMHIPALFTNPWFQFILATPVQFIIGWQFYVGAYKNLRNGGANMDVLVAVGTSAAYFYSI 240
TZNP NMHIPALFTNPWFQFILATPVQFIIGWQFYVGAYKNLRNGGANMDVLVAVGTSAAYFYSI 240
************************************************************
WT
YEMVRWLNGSTTQPHLYFETSAVLITLILFGKYLEARAKSQTTNALGELLSLQAKEARIL 300
TZNB YEMVRWLNGSTTQPHLYFETSAVLITLILFGKYLEARAKSQTTNALGELLSLQAKEARIL 300
TZNP YEMVRWLNGSTTQPHLYFETSAVLITLILFGKYLEARAKSQTTNALGELLSLQAKEARIL 300
************************************************************
WT
KDGNEVMIPLNEVHIGNTLIVKPGEKIPVDGKIIKGMTAIDESMLTGESIPVEKNVDDTV 360
TZNB KDGNEVMIPLNEVHIGNTLIVKPGEKIPVDGKIIKGMTAIDESMLTGESIPVEKNVDDTV 360
TZNP KDGNEVMIPLNEVHVGDTLIVKPGEKIPVDGKIIKGMTAIDESMLTGESIPVEKNVDDTV 360
**************:*:*******************************************
WT
IGSTMNKNGTITMTATKVGGDTALANIIKVVEEAQSSKAPIQRLADIISGYFVPIVVGIA 420
TZNB IGSTMNKNGTITMTATKVGGDTALANIIKVVEEAQSSKAPIQRLADIISGYFVPIVVGIA 420
TZNP IGSTMNKNGTITMTATKVGGDTALANIIKVVEEAQSSKAPIQRLADIISGYFVPIVVGIA 420
************************************************************
WT
LLTFIVWITLVTPGTFEPALVASISVLVIACPCALGLATPTSIMVGTGRAAENGILFKGG 480
TZNB LLTFIVWITLVTPGTFEPALVASISVLVIACPCALGLATPTSIMVGTGRAAENGILFKGG 480
TZNP LLTFIVWITLVTPGTFEPALVASISVLVIACPCALGLATPTSIMVGTGRAAENGILFKGG 480
************************************************************
WT
EFVERTHQIDTIVLDKTGTITNGRPVVTDYHGDDQTLQLLATAEKDSEHPLAEAIVNYAK 540
TZNB EFVERTHQIDTIVLDKTGTITNGRPVVTDYHGDDQTLQLLATAEKDSEHPLAEAIVNYAK 540
TZNP EFVERTHQIDTIVLDKTGTITNGCPVVTDYHGDDQTLQLLATAEKDSEHPLAEAIVNYAK 540
*********************** ************************************
WT
EKQLTLTETTTFKAVPGHGIEATIDHHHILVGNRKLVADNDISLPKHISDDLTHYERDGK 600
TZNB EKQLTLTETTTFKAVPGHGIEATIDHHHILVGNRKLVADNDISLPKHISDDLTHYERDGK 600
TZNP EKQLTLTETTTFKAVPGHGIEATIDHHHILVGNRKLMADNDISLPKHISDDLTHYERDGK 600
************************************:***********************
WT
TAMLIAVNYSLTGIIAVADTVKDHAKDAIKQLHDMGIEVAMLTGDNKSTAQAIAKQVGID 660
TZNB TAMLIAVNYSLTGIIAVADTVKDHAKDAIKQLHDMGIEVAMLTGDNKSTAQAIAKQVGID 660
TZNP TAMLIAVNYSLTGIIAVADTVKDHAKDAIKQLHDMGIEVAMLTGDNKNTAQAIAKQVGID 660
***********************************************.************
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WT
TVIADILPEEKAAQIAKLQQQGKKVAMVGDGVNDAPALVKADIGIAIGTGTEVAIEAADI 720
TZNB TVIADILPEEKAAQIAKLQQQGKKVAMVGDGVNDAPALVKADIGIAIGTGTEVAIEAADI 720
TZNP TVIADILPEEKAAQITKLQQQGKKVAMVGDGVNDAPALVKADIGIAIGTGTEVAIEAADI 720
***************:********************************************
WT
TILGGDLMLIPKAIYASKATIRNIRQNLFWAFGYNIAGIPIAALGLLAPWVAGAAMALSS 780
TZNB TILGGDLMLIPKAIYASKATIRNIRQNLFWAFGYNIAGIPIAALGLLAPWVAGAAMALSS 780
TZNP TILGGDLMLIPKAIYASKATIRNIRQNLFWAFGYNIAGIPIAALGLLAPWVAGAAMALSS 780
************************************************************
WT
VSVVTNALRLKKMRLEPRRKDA 802
TZNB VSVVTNALRLKKMRLEPRRKDA 802
TZNP VSVVTNALRLKKMRLEPRRKDA 802
**********************

TZNB – no mutation
TZNP – K144R, I315V, N317D, R504C, V577M, S648N, A676T
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Lead, cadmium, zinc and mercury transporting ATPase (2)
WT
MSNNKKHQNHEHHSHQEHENHTSHGNHEHHHHGNFKSKFFISLIFAIPIIILSPMMGVKL 60
TZNB MSNNKKHQNHEHHSHQEHENHTSHGNHEHHHHGNFKSKFFISLIFAIPIIILSPMMGVKL 60
************************************************************
WT
PFQISFTGSDWIVLILATILFFYGGKPFLSGAKDEISTKKPGMMTLVALGISVAYIYSLY 120
TZNB PFQISFTGSDWIVLILATILFFYGGKPFLSGAKDEISTKKPGMMTLVALGISVAYIYSLY 120
************************************************************
WT
AFYMNNFSGSSTHTMDFFWELATLILIMLLGHWIEMNAVGNAGNALKKMAELLPNTAVKL 180
TZNB AFYMNNFSGSSTHTMDFFWELATLILIMLLGHWIEMNAVGNAGNALKKMAELLPNTAVKL 180
************************************************************
WT
IDNNQREEVKISDIHIDDIVEVRAGESIPTDGIIVQGETSIDESLVTGESKKVHKTHNDD 240
TZNB IDNNQREEVKISDIHIDDIVEVRAGESIPTDGIIVQGETSIDESLVTGESKKVHKTHNDD 240
************************************************************
WT
VIGGSINGSGTVQVKVTATGENGYLSQVMGLVNQAQNDKSKAELLSDKVAGYLFYFAVSI 300
TZNB VIGGSINGSGTVQVKVTATGENGYLSQVMGLVNQAQNDKSKAELLSDKVAGYLFYFAVSI 300
************************************************************
WT
GLISFIVWMLIQNNVDFALERLVTVLVIACPHALGLAIPLVTARSTSIGAHNGLIIKNRE 360
TZNB GLISFIVWMLIQNNVDFALERLVTVLVIACPHALGLAIPLVTARSTSIGAHNGLIIKNRE 360
************************************************************
WT
SVEIAQHIDYIMMDKTGTLTEGNFSVNHYESFTDELNNEEILSLFASLESNSNHPLATGI 420
TZNB SVEIAQHIDYIMMDKTGTLTEGNFSVNHYESFTDELNNEEILSLFASLESNSNHPLATGI 420
************************************************************
WT
VDFAKGKNISYATPQEVNNIPGVGLEGTVDNKKLKIVNVSYLDKSNFDYNKEQFTNLAQQ 480
TZNB VDFAKGKNISYATPQEVNNIPGVGLEGTVDNKKLKIVNVSYLDKSNFDYNKEQFTNLAQQ 480
************************************************************
WT
GNSISYLIHDRQVIGIIAQGDKIKESSKQMVSDLLSRNITPVMLTGDNKEVAQTVAEELG 540
TZNB GNSISYLIHDRQVIGIIAQGDKIKESSKQMVSDLLSRNITPVMLTGDNKEVAQTVAEELG 540
************************************************************
WT
ISDVHAQLMPEDKESIIQDYQSNGSKIMMVGDGINDAPSLIRADIGMAIGAGTDVAIESG 600
TZNB ISDVHAQLMPEDKESIIQDYQSNGSKIMMVGDGINDAPSLIRADIGMAIGAGTDVAIESG 600
************************************************************
WT
DVILVKSNPSDIINFLSLSKNTMKKMVQNLWWGAGYNVIAVPLAAGILASIGLILSPAVG 660
TZNB DVILVKSNPSDIINFLSLSKNTMKKMVQNLWWGAGYNVIAVPLAAGILASIGLILSPAVG 660
************************************************************
WT
AILMSLSTIIVAINAFTLKLK 681
TZNB AILMSLSTIIVAINAFTLKLK 681
*********************

TZNB – no mutation
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Phosphoserine phosphatase (based on bioinformatics)
WT
MKKILFDVDGVFLSEERCFDVSALTVYELLMDKCYLGLHSHIDWETLTDNDIQDIRNRIF 60
TZNB MKKILFDVDGVFLSEERCFDVSALTVYELLMDKCYLGLHSHIDWETLTDNDIQDIRNRIF 60
TZNP MKKILFDVDGVFLSEERCFDVSALTVYELLMDKCYLGLHSHIDWETLTDNDIQDIRNRIF 60
************************************************************
WT
QKDKILNKLKSLGLNSNWDMLFIVFSIHLIDILKKLSHDEIEAFMYQDKPVELKLQNIST 120
TZNB QKDKILNKLKSLGLNSNWDMLFIVFSIHLIDILKKLSHDEIEAFMYQDKPVELKLQNIST 120
TZNP QKDKILNKLKSLGLNSNWDMLFIVFSIHLIDILKKLSHDEIEAFMYRDEPVELKLQNIST 120
**********************************************:*:***********
WT
NLADRFNLNEQLPLQFLDNVKVGKNNIYAALEEFAITELHVSDATLFSLKGALWTLAQEV 180
TZNB NLADRFNLNEQLPLQFLDNVKVGKNNIYAALEEFAITELHVSDATLFSLKGALWTLAQEV 180
TZNP NIADRFNLNEQLPLQFLDNVKVGKNNIYAALEEFATTELHVSDANLFSLKGALWTLAQEV 180
*:********************************* ********.***************
WT
YQEWYLGSKLYEEVEKKIARTTFKTGYIYQEIILRPVDEVKVLLNDLKGAGFELGIATGR 240
TZNB YQEWYLGSKLYEEVEKKIARTTFKTGYIYQEIILRPVDEVKVLLNDLKGAGFELGIATGR 240
TZNP YQEWYLGSKLYEEVEKKIARTTFKTGYIYQEIILRPVDEVKVLLNDLKGAGFELGIATGR 240
************************************************************
WT
PYTETVVPFENLGLLPYFEADFIATASDVLEAENMYPQARPLGKPNPFSYIAALYGNNRD 300
TZNB PYTETVVPFENLGLLPYFEADFIATASDVLEAENMYPQARPLGKPNPFSYIAALYGNNRD 300
TZNP PYTETVVPFENLGLLPYFEADFIATASDVLEAENMYPQARPLGKPNPFSYIAALNGNKRD 300
****************************************************** **:**
WT
KYESYINKQDNIVNKDDVFIVGDSLADLLSAQKIGATFIGTLTGLKGKDAASELEAHHAD 360
TZNB KYESYINKQDNIVNKDDVFIVGDSLADLLSAQK--------------------------- 333
TZNP KYESYINKQDNIVNKDDVFIVGDSLADLLSAQKIGATFIGTLSGLKGKDAAGELEAHHAD 360
*********************************
WT
YVINHLGELRGVLDNL 376
TZNB ---------------TZNP YVINHLGELRGVLDN- 375

TZNB – I334*
TZNP – 107R, K109E, L122I, I156T, T165N, Y295N, N298K, L376*
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Phosphoserine Phosphatase Clone Alignment
WT
MKKILFDVDGVFLSEERCFDVSALTVYELLMDKCYLGLHSHIDWETLTDNDIQDIRNRIF 60
TZNB MKKILFDVDGVFLSEERCFDVSALTVYELLMDKCYLGLHSHIDWETLTDNDIQDIRNRIF 60
************************************************************
WT
QKDKILNKLKSLGLNSNWDMLFIVFSIHLIDILKKLSHDEIEAFMYQDKPVELKLQNIST 120
TZNB QKDKILNKLKSLGLNSNWDMLFIVFSIHLIDILKKLSHDEIEAFMYQDKPVELKLQNIST 120
************************************************************
WT
NLADRFNLNEQLPLQFLDNVKVGKNNIYAALEEFAITELHVSDATLFSLKGALWTLAQEV 180
TZNB NLADRFNLNEQLPLQFLDNVKVGKNNIYAALEEFAITELHVSDATLFSLKGALWTLAQEV 180
************************************************************
WT
YQEWYLGSKLYEEVEKKIARTTFKTGYIYQEIILRPVDEVKVLLNDLKGAGFELGIATGR 240
TZNB YQEWYLGSKLYEEVEKKIARTTFKTGYIYQEIILRPVDEVKVLLNDLKGAGFELGIATGR 240
************************************************************
WT
PYTETVVPFENLGLLPYFEADFIATASDVLEAENMYPQARPLGKPNPFSYIAALYGNNRD 300
TZNB PYTETVVPFENLGLLPYFEADFIATASDVLEAENMYPQARPLGKPNPFSYIAALYGNNRD 300
************************************************************
WT
KYESYINKQDNIVNKDDVFIVGDSLADLLSAQKIGATFIGTLTGLKGKDAASELEAHHAD 360
TZNB KYESYINKQDNIVNKDDVFIVGDSLADLLSAQKIGATFIG-------------------- 340
****************************************
WT
YVINHLGELRGVLDNL 376
TZNB ----------------

TZNB - T341*
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DNA-directed RNA Polymerase alpha subunit
WT
MIEIEKPRIETIEISEDAKFGKFVVEPLERGYGTTLGNSLRRILLSSLPGAAVKYIEIEG 60
TZNB MIEIEKPRIETIEISEDAKFGKFVVEPLERGYGTTLGNSLRRILLSSLPGAAVKYIEIEG 60
TZNP MIEIEKPRIETIEISEDAKFGKFVVEPLERGYGTTLGNSLRRILLSSLPGAAVKYIEIEG 60
************************************************************
WT
VLHEFSAVDNVVEDVSTIIMNIKQLALKIYSEEDKTLEIDVRDEGEVTASDITHDSDVEI 120
TZNB VLHEFSAVDNVVEDVSTIIMNIKQLALKIYSEEDKTLEIDVRDEGEVTASDITHDSDVEI 120
TZNP VLHEFSAVDNVVEDVSTIIMNIKQLALKIYSEEDKTLEIDVRDEGEVTASDITHDSDVEI 120
************************************************************
WT
LNPELKIATVSKGGHLKIRLVANKGRGYALAEQNNTSDLPIGVIPVDSLYSPVERVNYTV 180
TZNB LNPELKIATVSKGGHLKIRLVANKGRGYALAEQNNTSDLPIGVIPVDSLYSPVERVNYTV 180
TZNP LNPELKIATVSKGGHLKIRLVANKGRGYALAEQNNTSDLPIGVIPVDSLYSPVERVNYTV 180
************************************************************
WT
ENTRVGQSSDFDKLTLDVWTNGSITPQESVSLAAKIMTEHLNIFVGLTDEAQNAEIMIEK 240
TZNB ENTRVGQSSDFDKLTLDVWTNGSITPQESVSLAAKIMTEHLNIFVGLTDEAQNAEIMIEK 240
TZNP ENTRVGQSSDFDKLTLDVWTNGSITPQESVSLAAKIMTEHLNIFVGLTDEAQNAEIMIEK 240
************************************************************
WT
EEDQKEKVLEMSIEELDLSVRSYNCLKRAGINSVQELADKSEADMMKVRNLGRKSLEEVK 300
TZNB EEDQKEKVLEMSIEELDLSVRSYNCLKRAGINSVQELADKSEADMMKVRNLGRKSLEEVK 300
TZNP EEDQKEKVLEMSIEELDLSVRSYNCLKRAGINSVQELADKSEADMMKVRNLGRKSLEEVK 300
************************************************************
WT
YKLEDLGLGLRKED 314
TZNB YKLEDLGLG----- 309
TZNP YKLEDLGLGLRKED 314
*********

TZNB – L310*
TZNP – no mutations
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DNA-directed RNA Polymerase beta subunit
WT
MAGQVVQYGRHRKRRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTG 60
TZNB MAGQVVQYGRHRKRRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTG 60
TZNP MAGQVVQYGRHRKRRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTG 60
************************************************************
WT
NLSLEFVDYRLGEPKYDLEESKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPLMT 120
TZNB NLSLEFVDYRLGEPKYDLEESKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPLMT 120
TZNP NLSLEFVDYRLGEPKYDLEESKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPLMT 120
************************************************************
WT
DTGTFVINGAERVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNRGAWLEYETDAKDVV 180
TZNB DTGTFVINGAERVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNRGAWLEYETDAKDVV 180
TZNP DTGTFVINGAERVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNRGAWLEYETDAKDVV 180
************************************************************
WT
YVRIDRTRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERL 240
TZNB YVRIDRTRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERL 240
TZNP YVRIDRTRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERL 240
************************************************************
WT
RPGEPPTVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETG 300
TZNB RPGEPPTVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETG 300
TZNP RPGEPPTVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETG 300
************************************************************
WT
EIVVEEGTVLDRRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDEEGRTT 360
TZNB EIVVEEGTVLDRRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDEEGRTT 360
TZNP EIVVEEGTVLDRRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRTT 360
******************************************************:*****
WT
TVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFR 420
TZNB TVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFR 420
TZNP TVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFR 420
************************************************************
WT
IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELT 480
TZNB IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELT 480
TZNP IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELT 480
************************************************************
WT
HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG 540
TZNB HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG 540
TZNP HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG 540
************************************************************
WT
FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT 600
TZNB FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT 600
TZNP FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT 600
************************************************************
WT
VMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTG 660
TZNB VMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTG 660
TZNP VMAKEKMDYMDVSQKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTG 660
************* **********************************************
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WT
MEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSG 720
TZNB MEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSG 720
TZNP MEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSG 720
************************************************************
WT
TCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERL 780
TZNB TCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERL 780
TZNP TCYNQRPIVAVGDVVEFNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERL 780
****************:*******************************************
WT
VKDDVYTSIHIEEYESEARDTKLGPEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDI 840
TZNB VKDDVYTSIHIEEYESEARDTKLGPEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDI 840
TZNP VKDDVYTSIHIEEYESEARDTKLGPEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDI 840
************************************************************
WT
LVGKVTPKGVTELTAEERLLHAIFGEKAREVRDTSLRVPHGAGGIVLDVKVFNREEGDDT 900
TZNB LVGKVTPKGVTELTAEERLLHAIFGEKAREVRDTSLRVPHGAGGIVLDVKVFNREEGDDT 900
TZNP LVGKVTPKGVTELTAEERLLHAIFGEKAREVRDTSLRVPHGAGGIVLDVKVFNREEGDDT 900
************************************************************
WT
LSPGVNQLVRVYIVQKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPL 960
TZNB LSPGVNQLVRVYIVQKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPL 960
TZNP LSPGVNQLVRVYIVQKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPL 960
************************************************************
WT
GVPSRMNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEEAGMARDGKTVLYDG 1020
TZNB GVPSRMNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEEAGMARDGKTVLYDG 1020
TZNP GVPSRMNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEEAGMARDGKTVLYDG 1020
************************************************************
WT
RTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEV 1080
TZNB RTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEV 1080
TZNP RTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEV 1080
************************************************************
WT
WALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGL 1140
TZNB WALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGL 1140
TZNP WALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGL 1140
************************************************************
WT
DVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKEVTD 1183
TZNB DVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKEVTD 1183
TZNP DVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKEVTD 1183
*******************************************

TZNB – no mutations
TZNP – E355D, P614Q, Y737F
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Thioredoxin-fold Protein
WT
MAGELRIMENKSREDINLSPVSKIEIYSFFDPFSSDCFKLSAILSKLRIEYNQYIRIRHI 60
TZNB MAGELRIMENKSREDINLSPVSKIEIYSFSDPFSSDCFKLSAILSKLRIEYNQYIRIRHI 60
TZNP MAGELRIMENKSREDINLSPVSKIEIYSFFDPFSSDCFKLSAILSKLRIEYNQYIRIRHI 60
***************************** ******************************
WT
LNPSLKVLTKCQAQSTSNFDNIALAYKAAELQGRVRAERFIHLMQNEIIPKRDIITESMI 120
TZNB LNPSLKVLTKCQAQSTSNFDNIALAYKAAELQGRVRAERFIHLMQNEIIPKRDIITESMI 120
TZNP LNPSLKVLTKCQAQSTSNFDNIALAYKAAELQGRLRAERFIHLMQNEIIPKRDIITESMI 120
**********************************:*************************
WT
CDCIQNAGIDLEVFKDDLQKSKLTESLKIDLHIAREMEIEQAPSLVFFSEDVHEEGLKVE 180
TZNB CDCIQNAGIDLEVFKDDLQKSKLTESLKIDLHIAREMEIEQAPSLVFFSEDVHEEGLKVE 180
TZNP CDCIQNAGIDLEVFKDDLQKSKLTESLKIDLHIAREMEIEQAPSLVFFSEDVHEEGLKVE 180
************************************************************
WT
GLYPYHIYTYIINELMGKPIEKNLPPKLETYIQQQQLVTMEELLTIYEWPEKLLNKELKK 240
TZNB GLYPYHIYTYIINELMGKPIEKNLPPKLETYIQQQQLVTMEELLTIYEWPEKLLNKELKK 240
TZNP GLYPYHIYTYIINELMGKPIEKNLPPKLETYIQQQQLVTMEELLTIYEWPEKLLNKELKK 240
************************************************************
WT
LAIQQKIEKLKYPDGDFWKSKMPKIKSK 268
TZNB LAIQQKIEKLKYPDGDFWKSKMPKIKSK 268
TZNP LAIQQKIEKLKYPDGDFWKSKMPKIKSK 268
****************************

TZNB – F30S
TZNP – V95L
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Table 1: Strains and plasmids used in this study
Strain/plasmid
E. coli
TOP10F´
S. aureus
RN4220
pCM29
RN4220/pCM29
RN4220/pCM29 variant

Genotype/properties

Reference

Cloning strain

Invitrogen

Restriction deficient cloning host
sGFP expression vector, CamR
Cloning host with pCM29
Cloning host with pCM29 and gene of interest

105
106

This study
This study
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Table 2: List of primers and their respective protein/gene in S. aureus
Primer
Sequence
CLM531 GGCTCATATTTGCTTTTTAAAAGC

Protein/Gene
Sequencing Primer
pCM29
CLM539 GGCTCGTATGTTGTGTGGAATTG
Sequencing Primer
pCM29
Thio F
TAAGCAGGTACCATTAATTGTAGGT
Thioredoxin-fold
protein
Thio R
TGCTTAGAGCTCACGAGGTCTTTAATTTATTTA
Thioredoxin-fold
protein
L11 Meth TACACAGGTACCAGGGAGAATAAAGTATGAACT Ribosomal protein L11
F
methyltransferase
L11 Meth TGCTTAGAGCTCATAACGTTGCACATTATTCAC
Ribosomal protein L11
R
methyltransferase
B Pol F
TAAGTAGGTACCTGAGGGGTGAATCTGTTTGG
DNA-directed RNA
Polymerase beta
subunit
B Pol R
TGCTTAGAGCTCCCTGTTTTGTAAATTGAGTA
DNA-directed RNA
Polymerase beta
subunit
Metal
TAAGTAGGTACCAATCACAGGGAGGCAATAAT
Lead, cadmium, zinc
ATP F
and mercury
transporting ATPase
Metal
TGCTTAGAGCTCTCCTTCATTATTAAGGAATC
Lead, cadmium, zinc
ATP R
and mercury
transporting ATPase
Phos F
TAAGCAGGTACCTCAGAAATGGAGTGGGGATT
Phosphoserine
Phosphatase
Phos R
TGCTTAGAGCTCGTTCCAATAAACGTTGCACC
Phosphoserine
Phosphatase
LysR F
TAAGCAGGTACCTTTTTGAAAGAGGTAAGTTC
Transcriptional
regulator, LysR family
LysR R
TGCCGAGAGCTCTTTTTAGATTTGAAATTTAT
Transcriptional
regulator, LysR family
A Pol F
TAAGCAGGTACCGTATATAAGGAGGATATTTAA DNA-directed RNA
Polymerase alpha
subunit
A Pol R
TGCTTAGAGCTCTTTATCAATCTTCTTTCTTCA
DNA-directed RNA
Polymerase alpha
subunit
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Figure 3: Map of pCM29 with the AmpR and CamR genes indicated for selection in E. coli and
S. aureus. Genes of interest were cloned in place of the GFP gene at restriction sites KpnI and
SacI under control of the PsarA promoter.
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Appendix B: Selected NMR Spectra for Synthesized Compounds
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